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Treatment of cutaneous wounds with poly-N-acetyl-glucosamine nanofibers 
(pGlcNAc), a novel polysaccharide material derived from a marine diatom, results 
in increases in wound closure, antibacterial activities and innate immune 
responses. Treatment with nanofibers results in increased defensin, small 
antimicrobial peptides, expression both in vitro and in vivo. Induction of defensing 
expression results in bacterial clearance in a cutaneous wound model.  We have 
also shown that Akt1 plays a central role in the regulation of these activities. We 
show that  pGlcNAc treatment of cutaneous wounds in mice results in decreased 
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scar sizes. Additionally, treatment of cutaneous wounds with pGlcNAc results in 
increased elasticity and a rescue of tensile strength. Masson Trichrome staining 
suggests that pGlcNAc treated wounds exhibit decreased collagen content as 
well as increased collagen alignment with collagen fibers oriented similarly to 
unwounded tissue. Utilizing a fibrin gel assay to analyze the effect of pGlcNAc 
nanofiber treatment on fibroblast alignment in vitro, pGlcNAc stimulation of 
embedded fibroblasts results in fibroblasts alignment as compared to untreated 
controls, by a process that is Akt1 dependent.  Our data shows that in Akt1 null 
animals pGlcNAc treatment does not increase tensile strength or elasticity. 
Taken together, our findings suggest that pGlcNAc nanofibers stimulate an Akt1 
dependent pathway that results in wound closure, the proper alignment of 
fibroblasts, decreased scarring, and increased tensile strength during cutaneous 






The primary function of human skin is as a barrier against the environment.  
Once this protective barrier is lost, the process of wound healing quickly begin in 
an attempt to prevent further injury or illness. In the United States over 1 million 
people suffer from burns [1] and another 6.5 million suffer from chronic skin 
wounds annually.  Recent advances in cell and molecular biology have allowed 
for a better understanding of proper wound healing but also requirements for 
tissue regeneration. The primary goals of wound treatment are rapid closure and 
a functional and esthetic scar [2].  Wound healing is an intricate process that 
requires collaborative efforts of different tissues and involves complex 
interactions between different cell types, cytokines, and growth factors.  The 
classic model of wound healing can be divided into four sequential, yet 
overlapping phases:  hemostasis, inflammation, proliferation, and remodeling and 
maturation.  Figure 1.1 depicts the phases of cutaneous wound healing.  
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Hemostasis 
Immediately following injury coagulation and hemostasis take place within the 
wound [3, 4].   The injured vasculature constricts followed by activation of the 
coagulation cascade by the endothelium and the platelets.  As blood enters the 
wound site, platelets quickly come into contact with exposed collagen and other 
extracellular matrix components triggering clot formation. The formation of the 
clot, which consists of collagen, platelets, fibronectin, and thrombin, funcitons as 
a protective shield but also a provisional matrix through which cells can migrate 
to facilitate repair  [3, 5].  Importantly, the clot also serves as a reservoir of 
concentrated cytokines and growth factors that are necessary for the initiation of 
the wound healing process [5].  These growth factors and cytokines include, but 
are not limited to, Platelet Derived Growth Factor (PDGF), Vascular Endothelial 
Growth Factor (VEGF), Transforming Growth Factor Beta (TGFβ), Fibroblast 
Growth Factor (FGF), and Interleukin 1 (IL-1) (Table 1). Conditions that involve 
inadequate clot formation illustrate the importance of the hemostatic process to 
wound healing. For example, a deficiency of Factor XIII, which is necessary for 
stabilizing fibrin, is associated with impaired wound healing [6, 7] 
Inflammatory Phase 
Following clot formation, cellular signals are generated that result in recruitment 
of inflammatory cells to the wound site.  Neutrophils and monocytes are the 
predominant cells at the site of injury during the early stages while macrophages 
arrive during the later phase of inflammation [8]. Both neutrophils and monocytes 
are recruited to the site from circulation following changes in the endothelial cell 
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TABLE 1. Table illustrating Growth Factors and Cytokines  and their related 
function in wound healing .   
Table adapted from “Wound Healing--Aiming for Perfect Skin Regeneration.” 
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lining of the vasculature at the wound site [9].  Neutrophils arrive to the wound 
site within minutes of injury and serve to cleanse the wound of foreign particles 
and the initial influx of bacteria.  More recent studies show that neutrophils are 
also an important source of pro-inflammatory cytokines that may function as 
some of the earliest signals to activate keratinocytes and fibroblasts [10]. 
Neutrophil infiltration typically subsides after approximately 48 hours and 
macrophages become the predominant inflammatory cells.  Macrophages 
continue the clearance of debris and pathogenic organisms.  Additionally, once 
macrophages are activated, they release a myriad growth factors and cytokines 
at the wound site including TGFβ, TNFα, VEGF, PDGF, and FGF [5].  Since 
activated macrophage are responsible for clearing debris and releasing these 
important factors with known roles in granulation tissue formation, angiogenesis, 
and fibroblasts proliferation and recruitment, one could argue their importance as  
regulators of the transition between inflammation and repair. The necessity of 
macrophages to wound repair is even more evident after recent work utilizing 
animal models genetically engineered for inducible macrophage depletion.  Mice 
depleted of macrophage pre-injury show defects in re-epithelialization, 
granulation tissue formation, angiogenesis, and myofibroblast associated wound 
contraction [11, 12].  More recent data indicates functional phenotypes of 
macrophage exist.   Macrophages exhibiting a classical phenotype have been 
designated “M1” while other macrophages are designated alternative or “M2.” M1 
macrophages are considered to be proinflammatory while M2 cells are 
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considered anti-inflammatory and may play a critical role in tissue repair and 
remodeling [13] 
Proliferative Phase 
The proliferative phase is characterized by the formation of new blood vessels, 
granulation tissue, and collagen deposition by fibroblasts, keratinocyte 
proliferation and migration, and wound contraction.  An important component of 
the proliferative phase is epithelialization.  In response to cytokines and growth 
factors, wound margin epithelial cells proliferate and migrate over the wound bed 
to reestablish the protective barrier. Macrophage produce TGFα which stimulates 
epithelial proliferation [14] while fibroblasts synthesize and secrete keratinocyte 
growth factor (KGF) and IL-6 which stimulates keratinocytes to migrate into the 
wounded area and differentiate into the epidermis [15].    
The new connective tissue filled with numerous capillaries during the healing 
process is termed granulation tissue. During this time, macrophages provide 
growth factors that stimulate vascularization and fibroblasts produce the new 
extracellular matrix that is necessary for healing [2].  Angiogenesis, an essential 
step during the proliferative phase, is an intricate complex that is required to 
sustain the new tissue. While recent data shows that many molecules may be 
responsible for the induction of angiogenesis, the most common stimuli are FGF 
and VEGF production by macrophage and endothelial cells [2].  It has also been 
shown epidermal keratinocytes can secrete large amounts of VEGF during 
wound healing [16]. Structural proteins such as fibrin, fibronectin, and hyaluronic 
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acid help to form this provisional matrix, which serves as a scaffold for cell 
migration [17]. 
Maturation and Remodeling 
The remodeling and maturation phase of wound healing occurs for weeks up to a 
year after injury. Once abundant amounts of collagen have been deposited into 
the wound, the fibroblasts stop producing collagen and the granulation tissue is 
replaced with a scar.  Collagen remodeling is dependent on both the low rate of 
deposition and its catabolism [2].  Matrix metalloproteinases (MMPs), secreted by 
macrophages, epidermal cells, fibroblasts, and endothelial cells, are responsible 
for degradation of collagen in the wound [18] while a balance of MMPs and tissue 
inhibitors of metalloproteinases (TIMP) are required for repair.  Excessive 
collagen deposition can lead to hypertrophic scarring while more effective 
deposition will lead to a scar with decreased tensile strength of the healed wound 
[3].   
 The collagen in uninjured skin is approximately 90% type I and 10% Type III. 
During the stages of granulation tissue and early matrix formation of a healing 
wound, collagen type III makes up approximately 30%, but the ratio decreases 
back to normal levels in the mature scar [19].  Collagen synthesis and maturation 
continues for several weeks after wounding resulting in increased amounts of 
collagen and also  the deposition of thicker, more organized collagen fibers.  The 
final result of healing is the formation of a scar, as the collagen does not become 
as organized as the collagen found in uninjured skin [3].  Resultant wound 
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strength doesn’t return to normal level with tensile strength and reaches 
approximately 80% of the original strength one year post injury [20, 21].  
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Figure 1.1.  Illustration depicting the phases of cutaneous wound healing. (a) 
Immediately following injury, blood elements are present and neutrophils, 
platelets and plasma proteins infiltrate.  (b) Platelets aggregate with fibrin causing 
coagulation. (c) Platelets release several which attract PMNs to the wound. (d) 
Macrophages replace PMNs as the principal inflammatory cell. (e) The 
proliferation phase begins with fibroblasts being recruited to the site and begin to 
synthesize collagen. (f) Remodeling of collagen occurs for weeks to months after 
injury.   
Image adapted from Expert Reviews in Molecular Medicine: Vol. 5; 21 March 
2003 
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Wound Contraction 
Closure of cutaneous wounds involves epithelialization and matrix 
deposition, but also contraction to bring wound margins together.  Contraction of 
these underlying granulation tissue and extracellular matrix typically results in 
scar formation.  Most studies surrounding wound contraction focus on wound 
fibroblasts, which are normally quiescent, but become activated shortly after 
cutaneous wound healing [22].  As early as the 1950’s, investigators began to 
question which component of the healing wound was responsible for the tensile 
forces and contraction.  In 1972, Giabanni et al. demonstrated that isolated 
granulation tissue could undergo smooth muscle-like contraction in vitro and that 
specialized cells within this tissue shared features of smooth muscle cells such 
as actin filament bundles [22, 23].  The cells, now termed “myo-fibroblasts” were 
proposed to be responsible for force generation involved in wound contraction 
[22] and their presence in contractile tissues is fairly well known today.  
Myofibroblasts 
Myofibroblasts in cutaneous wounds arise from the differentiation of tissue 
fibroblasts and circulating fibrocyte progenitors [24], both of which migrate into 
the center of the wound site. Once the wound granulation tissue is populated with 
myofibroblasts expressing α-smooth muscle actin (α-SMA) contraction begins 
[25]. While the role of TGF-β in wound healing and scar formation is widely 
studied, data also indicates that TGF-β along with other growth factors and 
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cytokines play an important role in myofibroblast activation and therefore 
contraction. The addition of TGF-β in vitro greatly enhances the ability of 
fibroblasts to contract collagen gels [26].  TGF-β1 is now considered the most 
important growth factor in development and differentiation of myofibroblasts by 
inducing the expression of α-SMA [27] as well as a number of cytoskeletal 
proteins important for the contractile apparatus [28]. 
In addition to activation by growth factors, myofibroblast activation is also 
controlled by the mechanical microenvironment. Fibroblasts in normal 
unwounded tissue are stress-shielded by the crosslinked ECM, the protective 
structure is lost in injured tissue that is undergoing healing and remodeling [24].  
Studies using collagen gels to simulate in vivo environments help to elucidate the 
role of tension in myofibroblasts differentiation. Fibroblasts cultured in “floating 
gels” with a lack of tension show a lack of actin stress fiber formation. Fibroblasts 
cultured in attached gels, and therefore provided with of under tension, 
demonstrate the rapid appearance of actin stress fibers is seen, consistent with 
myofibroblast morphology [29].  
Stress Fibers 
Previous studies have shown that wound healing is associated with the 
appearance of these myofibroblasts, which contain prominent microfilament 
bundles (stress fibers) that exhibit contractile ability [30].  These stress fibers 
have been proposed to function as contractile organelles of the cell [31].  Stress 
fibers contain bundles of 10-30 actin filaments and are held together by actin 
crosslinking protein α-actinin [32]. More specifically, the contractile apparatus 
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formed by myofibroblast is composed, at least in part, of F-actin microfilament 
bundles, α-actinic and non muscle myosin[33]. While some functions of 
myofibroblasts in wound healing remain unclear, evidence suggests a role for 
both contraction and mediation of extracellular matrix and remodeling [34].  
Interesting, studies in corneal myofibroblasts have demonstrated that these cells 
establish an interconnected meshwork in which other cells and cellular processes 
temporally orient parallel to the wound margins during contraction [35].  Petroll et 
al. reports, at least in rabbit corneal healing, the stress fibers develop a unique 
pattern of alignment parallel to the long axis of the wound [33].  Comparison of 
fibrobalsts expressing various levels of α-SMA suggests increased α-SMA 
expression enhances fibroblast contractile activity [36]. The signaling required for 
formation and maintenance of the actin stress fiber apparatus is mediated by 
Rho GTPases [37].  While further studies are required to clarify the many 
funcitons of the myofibroblasts, it is clear that the actin cytoskeleton is critical to 
the role in wound healing.   
Tensile Strength 
The skin has important protective functions against mechanical trauma such as 
friction, impact, pressure, cutting, and shear [38].  Initially after tissue injury, 
tensile strength of healing skin is fairly weak due the disorganization of the newly 
formed collagen and extracellular matrix.  While collagen and ECM is remodeled 
to better resist mechanical force, the final tensile strength of the healed wound 
never reached the strength of uninjured tissue.  Over time, the matrix in the 
healing wound changes.  The thinner collagen fibers that are deposited after 
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injury organize along the stress of the wound which results in increased tensile 
strength [39].  Collagen fibers and the ECM continue to go through remodeling 
for up to 1 year, but after three months of healing wound tensile strength does 
not exceed 80% of unwounded tissue [40].   
Insights from Fetal Wound Healing 
The primary goal of wound healing treatment is to induce rapid closure but also 
produce a functional and esthetic scar.  In contrast to adult wound healing, early 
gestation fetal wounds remarkably heal without scar.  Scarless fetal wound 
healing has been confirmed in both animal models and humans [41].  Scarless 
healing is age dependent, with human embryos exhibiting normal scarring after 
24 weeks of gestation and mice begin scarring on embryonic day 18.5 [41, 42] 
Initially, scarless fetal healing was thought to be a result of the environment in 
utero. Investigators hypothesized that the lack of bacteria and inflammatory 
mediators in the amniotic fluid resulted in scarless repair. Supporting data shows 
fetuses that are challenged with bacteria or artificially stimulated to produce an 
inflammatory response heal with normal scarring [43, 44]. Conversely, other 
groups showed adult skin that is placed in the fetal environment heals with 
normal scar formation [45].  Additionally, marsupials, which develop outside of 
the uterus heal without scar [46] indicating that the uterine environment alone 
cannot account for the phenomenon of scar-free healing.  Much of the current 
wound healing research is geared toward understanding the differences between 
adult and fetal wound healing in an effort to better understand the mechanisms 
underlying tissue regeneration and scar formation.  While the exact mechanistic 
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differences between fetal and adult wound healing remain unknown, significant 
differences exist among the inflammatory responses, extracellular matrix, cellular 
mediators, and gene expression profiles of fetal and postnatal wounds [41]. Many 
of the critical proteins necessary for normal adult wound healing differ in 
expression or their expression patterns in fetal wound healing.  
In contrast to adult epidermal cells that crawl across the wound bed, embryonic 
epidermal cells are pulled across the wound by actin fiber contraction [47] which 
causes a rapid reepithelialization.  This actin cable assembles almost 
immediately after injury and requires Rho, a GTPase, for re-epithelialization [48].  
Additionally, many growth factors and cytokines show differential expression 
during fetal wound healing. The differential expression of TGFβ appears to be 
critical to the lack of scarring seen in fetal wounds.  Embryonic wounds show a 
rapid induction of TGFβ1, a pro-scarring cytokine, shortly after wounding, but a 
rapid clearance and return to background levels [49]. This is in comparison to 
adult wounds which express high levels of TGFβ1 through out the duration of the 
healing process [5]. Neutralization of TGFβ1 and TGFβ2 during wound healing 
results in reduced scarring [50] while application of exogenous TGFβ3 has a 
similar effect [51].  These studies indicate that the balance of TGFβ isoforms may 
play a critical role in scarless repair.  TABLE 1.3 illustrates that a number of 
differences  when comparing adult to fetal healing.  
The variances between adult and fetal extracellular matrix may also play a critical 
role in scarless repair. In fetal wounds, type III collagen is deposited in a fine, 
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reticular pattern that is indistinguishable from normal skin [52] while postnatal 
wounds show a higher proportion of collagen type I [53].  Additionally, there are  
 
 
 Table 1.3.   Fetal vs. Adult Wound Healing.  Table is adapted from       
Namazi et al., 2010 [54] and highlights differences seen when comparing fetal 
wound healing to normally scarring adult healing 
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differences in extracellular matrix modulators such as decorin and fibromodulin. 
Levels of decorin, a proteoglycan that is known to regulate fibrillogenesis of 
collagen, is up-regulated in adult wounds [55] and decreased expression is 
associated with pathological scarring in adult models of healing [56]. 
Fibromodulin, also a modulator of collagen fibrillogenesis is decreased in adult 
wounds. Interestingly, these extracellular matrix modulators are known to interact 
with and affect TGFβ expression, which plays an important role in cutaneous 
scarring [57, 58].  Granulation tissue and myofibroblast expression also plays an 
important role in the contraction of adult wounds. The presence of 
myofibroblasts, which are differentiated fibroblasts that express α-smooth muscle 
actin, is controversial in fetal wound healing.  Both mouse and sheep fetal 
models have been shown to lack α-smooth muscle positive fibroblasts [59] but 
other groups have shown presence of myofibroblasts in fetal wounds at earlier 
time points [60].  Fetal wounds also exhibit increased expression of matrix 




Defensins are small (3-4 kDa), cysteine-rich cationic antimicrobial peptides found 
in mammals, insects, and plants that contribute to host defense against 
infections.  These peptides are classified into subfamilies (α, β, and θ) based on 
their pattern of disulfide bonding. Antimicrobial peptides carry an average of 40-
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50% hydrophobic residues arranged so that the folded peptide is an amphipathic 
structure [62].   Alpha defensins (α-defensins) are 29-35 amino acids in length 
maintain the specific cysteine arrangement of C1-C6, C2-C4, and C3-C5 
domains, and Beta defensins (β-defensins) are 38-42 amino acids in length and 
have  a C1-C5, C2-C4, C3-C6 cysteine connectivity.  HNP1-3 are nearly identical 
while sequence conservation is mainly limited to the 6 cysteines for the 
remaining defensins [63].  To date there have been six human α-defensins and 
four human β-defensins peptides well characterized, though there are many 
more that have been identified in the human genome. Human α-defensins 1-4, 
also referred to as human neutrophil peptides (HNP1-4), are typically stored in 
the primary azurophilic granules of neutrophils, constituting 30-50% of the total 
protein of these organelles [64] while α-defensins 5 and 6 are typically found in 
paneth cells of the small intestine. Research has shown that rabbit alveolar 
macrophages possess α-defensins in levels comparable to rabbit neutrophils [65] 
indicating defensins are not strictly limited to neutrophil granules. HNPs are 
released by degranulation of granules in response to proinflammatory stimuli or 
bacterial stimuli [66].   
β-defensins represent the largest family of vertebrate defensins and are 
constitutively expressed by epithelial cells of the tracheobronchial lining, skin, 
and kidney where they can be up-regulated in response to infectious or 
inflammatory stimuli [67].   θ-defensins comprise the most recently identified 
subfamily of defensins.  θ-defensins were discovered in the rhesus monkey and 
are expressed only in Old World monkeys, lesser apes, and orangutans [63].  
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Figure 1.2.   Function of Defensins.  An Illustration depicting the known various 
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Interestingly, the genes that encode θ-defensins are mutated α-defensins which 
contain a premature stop codon, resulting in a stop in translation after only 12 
residues.  While the mechanism is unknown, two of these truncated peptides are 
spliced together to form a cyclical θ-defensins [63]. 
Discovery 
Approximately fifty years ago, researchers began to focus on the antimicrobial 
properties of leukocyte extracts. Leukin and phagocytin, acidic extracts from 
rabbit PMNs, were discovered to be antimicrobial against bacteria [63]. In 1985, 
these antimicrobial peptides were renamed defensins and recognized as natural 
peptide antibiotics [63]. In 1991, the first β-defensins were discovered and 
isolated from bovine trachea al epithelium [68].  Today, β-defensins are much 
more numerous than their counterpart and interestingly exist in reptiles, 
suggesting their existence prior to α-defensins [63].  
Defensin synthesis and processing 
Neutrophil defensins are synthesized in the bone marrow in neutrophil precursor 
cells [69] as precursor peptides,   encoded as a prepropeptide that contains an 
amino (N)-terminal signal sequence, a propiece, and a (C)-terminal mature 
cationic defensin [70].  Ganz et al showed that processing of human neutrophil 
defensins involves sequential cleavage of the preprodefensin to a prodefensin 
form and then eventually to a mature defensin [70].  While the processing of 
Paneth Cell defensins (α-defensins 5-6) are similar to that of human neutrophil 
defensins, the activity of these defensins requires proteolytic activation by matrix 
metalloproteinase-7 [71].  The β-defensin precursor structure is simpler than that  
	   19	  
 
 
Figure 1.3.  Schematic of defensing processing.  Neutrophil defensins 
involves sequential cleavage of the preprodefensin to a prodefensin form and 
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of α-defensins.  The structure of the β-defensin precursor consists of signal 
sequence, a short propiece, and the mature defensin peptide at the C-terminus 
[72] 
Defensin Activity 
These small peptides are important effectors of innate immunity; possessing 
antimicrobial properties that are active against gram positive and negative 
bacteria, fungi, and many viruses.  Despite a growing volume of literature on their 
role in the innate immune response, details of the mechanism of defensin 
mediated microbial killing is somewhat unclear.  However, studies suggest that 
the cationic characteristics of the defensins allow them to interact with microbial 
membranes, forming pores which results in bacterial cell killing [72]; [73].  
Studies with E. coli revelaed that HNP1-3 permeabilized inner and outer 
membranes of bacteria.  This permeabilization coincided with termination of 
DNA, RNA, protein synthesis, and the loss of colony forming ability [74].   Recent 
evidence shows that α-defensin HNP-1 binds to lipid II, a cell wall precursor in 
the bacterial membrane suggesting that defensins inhibit cell wall synthesis.  
Furthermore, a decrease in lipid II resulted in decreased bacterial killing by HNP-
1 [75].  The non-specific antimicrobial mechanisms employed by defensins may 
make it difficult for bacteria to develop resistance, making them of great interest 
in the clinical arena.     
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While defensins are known antimicrobial agents, it has more recently come to 
light that these peptides exhibit biological activities beyond the inhibition of 
microbial cells.  Defensins have been shown to contribute to adaptive immune 
response by exhibiting chemotactic activity on dendritic cells [76] T cells, 
monocytes, and macrophages [77].  Recent evidence also suggests that β-
defensins can cause the recruitment of keratinocytes [78].  Both α- and β-
defensins were shown to exert chemotactic activity for dendritic cells both in vitro 
and in vivo [76]. β-defensins cross talk with the adaptive immune system by 
interacting with chemokine and Toll-like receptors on immune cells.  Human beta 
defensin-2 has been shown to interact with the CCR6 receptor in immature 
dendritic cells and T cells; recruiting these cells to sites of interest [79].  
Additionally, human β-defensin-3 demonstrates high affinity for CCR2 on myeloid 
cells resulting in chemoattraction in the absence of the natural ligand [80].    
While θ-defensins have comparable antimicrobial properties to α-defensins, their 
antiviral properties are far superior.  It has been reported that θ-defensins can 
protect cells from infection by HIV-1 in vitro [81] and herpes simplex virus type 1 
and 2 [82].  θ-defensins were shown to inhibit the formation of the HIV-1 proviral 
DNA, indicating that they most likely inhibited viral entry [83].  Recent studies 
have also indicated that θ-defensins show antiviral activity against Influenza A via 
impairment of the viral hemagglutinin [84].     
Defensins in Disease 
As described, defensins are advantageous in many situations, but there are 
instances when defensin expression may be potentially detrimental.   Defensins 
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are an imperative part of the host immune system, it is not surprising that they 
have been implicated in several conditions or diseases.  There is new evidence 
suggesting some of these molecules may promote neoplasia. Overexpression of 
human beta defensin-3 in solid tumors promotes selective chemoattraction of 
myeloid cells to the site and stimulates the secretion of pro-inflammatory 
cytokines that contribute to tumor growth [85].  Furthermore, increased 
expression of human beta defensins-2 and -3 were associated with oral cancer 
lesions [80].   
In Crohn’s disease, an inflammatory condition of the intestinal tract, it has been 
shown that defensin levels are indeed altered.  This disturbance in defensin 
levels may cause commensal bacteria to become pathogenic [86].  Skin 
diseases, such as psoriasis, show increased levels of human β-defensin- 2 and 
β-defensin-3 and as a result these lesions are rarely infected.  Indeed, psoriasis 
skin was the organ used to identify human production of β-defensin-2 and -3 [87].  
Conversely, atopic dermatitis shows decreased levels of β-defensin-2 and β-
defensin-3 resulting in a skin condition that is commonly accompanied by fungal, 
viral, and bacterial infections [88].  Symptoms resulting from Cystic Fibrosis, such 
as recurring infections and inflammation, may also be the result, at least in part, 
of disturbed defensin levels [89].  It has been documented that defensin activity is 
inhibited in high salt environments [72]. Cystic Fibrosis lung fluid has been 
reported to be extremely high in salt and it is this environment that may be 
responsible for the inhibition of defensin activity.          
Defensins in Wound Healing 
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Due to their antimicrobial and chemotactic effects, it is logical that defensins 
likely play an important role in wound healing. Evidence shows that defensins are 
stimulatory for epithelial cells and fibroblasts [90], two cell types that contribute 
greatly to the normal wound healing process. Niyonsaba et al. has demonstrated 
that β-defensins increased keratinocyte proliferation and migration [78].  
Additionally, human β-defensin-2 was shown to stimulate chemotaxis and 
mobility of human umbilical vascular endothelial cells in vitro as well as 
stimulating the formation of capillary networks in matrigel [91]. Human β- 
defensins can also up-regulate the transcription of MMPs and decrease that of 
TIMPs suggesting a role in tissue remodeling responses [92]. Hirsch et al. 
showed that human β-defensin-3 treatment of S. aureus infected wounds both 
decreased bacterial and increased wound closure, suggesting a potential 
therapeutic for diabetic wounds [93].  Furthermore, in vitro experimentation with 
airway epithelial cells show that α-defensins 1-3 caused a dose and time-
dependent increase of wound closure as well as increased cell migration that 
required activation of PI3-K and ERK1/2 pathways [94].  
AKT1 
Akt structure 
The Akt family of serine threonine kinases are known downstream effectors of 
phosphoinositol-3-kinase (PI3K). PI3K can be activated by numerous cellular 
stimuli, such as growth factors, G-protein coupled receptor activation, or integrin 
activation. This kinase is responsible for the conversion of phophoinositol 4,5 
phosphate (PIP2) to phosphoinositol 3,4,5 phosphate (PIP3). PIP3 formation at 
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the membrane is required for the recruitment of Akt  to the membrane to allow 
phosohorylation of the Thr 308 site by phospho- inositide- dependent kinase-1 
(PDK1) [95-97]. The second phosphorylation site, Ser473, is apparently 
controlled in an mTOR dependent nature (mTOR2/Rictor).  As shown in Figure 
1.4, the Akt subfamily is comprised of three isoforms (Akt1, Akt2, and Akt3).  The 
three mammalian isoforms, which are products of distinct genes, share a 
conserved structure that includes an N-terminal pleckstrin homology (PH) 
domain, a central kinase domain, and a C-terminal regulatory domain[98].  The 
three specific isoforms share approximately 80% homology [96, 99]. The PH 
domain binds phosphoinositides with high affinity, specifically 
phosphatidylinositol(3,4,5)trisphosphate (PIP3) or phosphatidylinositol 
(3,4)-bisphosphate (PIP2) [98].    The kinase domain which is located in 
the center, is structurally similar to other kinases such as PKC and PKA 
[100]. Akt1 is activated by phosphorylation of both Thr308, which is located in 
the activation loop of the kinase domain, and Ser473 located within the 
hydrophobic motif (HM) [96].   
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Figure 1.4.  Akt Isoforms.  Image illustrates the similarities and 
differences between the three isoforms of Akt.  Image adapted and partially 
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Akt1 signalling 
Akt, also known as protein kinase B (PKB), is a serine threonine protein kinase 
that has known roles in cell survival, migration, metabolism, and proliferation. Akt 
was originally identified as the oncogene in the transforming retrovirus Akt8 
[101].  The Akt family of serine threonine kinases are known downstream 
effectors of PI3K signaling. Activation of Akt requires recruitment to the plasma 
membrane and subsequent phosphorylation at the threonine and serine 
residues.  PI3-Kinase is activated and PIP2 (ILK) [102, 103] and the mammalian 
target of rapamyacin complex mTOR2 [104] are PDK2 molecules, although other 
molecules may also serve this role. PI3K activation can be regulated by the 
tumor suppressor PTEN by the dephosphorylation of PIP3 à PIP2 therefore 
decreasing the activity of Akt1[95]. While Akt1 signaling is complex, Figure 1.5 
illustrates Akt1 as a central regulator of many cellular functions depicts common 
targets for Akt.  
Akt function  
Akt is most well known for cell survival regulation and antiapoptotic, 
cancer promoting activity. BAD, a member of the Bcl-2 family of proteins that 
binds to promote apoptsis, but when phosphorylated by Akt1 pro-apoptotic 
activity is lost [105].  Akt has also been reported to phosphorylate Caspase-9, an 
initiator of apoptosis, resulting in ablation of its activity [106]. Furthermore, data 
shows that Akt can also regulate cell survival through modulation of  transcription 
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Figure 1.5.  Akt signaling. Above diagram depicts a simplified version of 
AKT signaling.  AKT plays a central role in many cellular functions including 
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factor activity.  The Forkhead family of transcription factors may be directly 
phosphorylated by Akt, resulting in inhibition of forkhead transcription factors and 
subsequent apoptosis [107].  Akt also inhibits IκB via the regulation of IKK 
activity, which leads to the nuclear translocation and activation of the 
transcription factor NFκB, resulting in transcription of pro-survival genes [108].  
  While the anti-apoptotic actions of Akt are heavily studied, Akt also 
regulates other cellular functions such as migration, protein synthesis, and 
glucose metabolism [109].  Several developmental studies have shown that 
activated PI3K/Akt contributes to EMT driven mesoderm formation [110].  
Furthermore, PI3K is required for TGFβ-mediated cell migration in mammary 
epithelial cells [111].  Interestingly, evidence shows that there may be isoform 
specific roles in cell migration. Additionally, Akt has been shown to be important 
for vascular homeostasis and angiogenesis.  Vascular Endothelial Growth Factor 
(VEGF) dependent effects on cell survival and migration have been shown to be 
regulated bu the Akt pathway [112] .   
Animal Models 
Akt1, Akt2, and Akt3 knockout animals exhibit mild phenotypes which suggests 
functional redundancy, but these animals are on a mixed background which may 
mask specific phenotypes. While this redundancy does exist, there is evidence 
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that supports each family member having distinct roles.  Akt1 is thought to act on 
cell size with Akt1 deficient animal exhibiting growth retardation and increased 
apoptosis [113] as well as neonatal mortality [114]. Akt2 is important for insulin 
induced glucose uptake [115].  Mice deficient for Akt2 display insulin resistance 
and a type 2 diabetic-like phenotype [116].   Recently, our lab has shown that 
Akt3 is involved in the regulation of mitochondrial biogenesis in endothelial cells 
[117]. 
To better to understand the in vivo roles of the PKB isoforms, animal models 
lacking various combinations of isoforms have been generated. Mice lacking both 
Akt1 and Akt2 exhibit severe growth deficiency, impaired skin and bone 
formation, and do not survive long after birth [118].  Mice deficient of both Akt1 
and Akt3 show numerous developmental abnormalities that prove lethal around 
embryonic day 11 [119].  The severe phenotypes and lethality associated with 
these double knockout animals reiterates functional redundancy in vivo.   
Conversely, Akt2/Akt3 knockout animals display growth deficiency, impaired 
glucose homeostasis, and decreased brain size, but survive postnatally [120].   
Akt1 in Wound Healing 
The PI3Kà Akt pathway has been shown to be a regulator of VEGF stimulated 
endothelial cell survival [112] and has been known to play a key role in the 
formation of new vessels, an essential component of healing. VEGF 
enhancement of endothelial cell motility and tubule formation is Akt dependent 
[121].  It has previously been shown that  Akt mutations result in abnormal 
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tracheal formation in Drosophila, a model system for tubulogenesis [122].  In 
addition to its known role in angiogenesis, Akt1 has also been implicated as a 
regulator of tissue growth, which is evident in mice lacking Akt1 that exhibit 
growth retardation [113]. 
An interesting study by Zhao et al., based on the premise that disruption of the 
epithelial layer generates endogenous electric fields that are important for 
wound, shows that the PI3K pathway is essential to these cues.  These electric 
fields are decreased upon ablation of PI3K, abolishes directed cell movement 
and migration during the healing process [123].  Recent work to further elucidate 
the PI3KàAktà mTOR pathway in wound healing shows that mTOR activation 
can enhance epithelial cell proliferation, migration, and wound healing, while 
pharmacological inhibition of mTOR delays wound closure [104].  Interestingly, 
several molecular pathways involved in cancer cell progression have recently 
been shown to also promote tissue regeneration [124].  As the PI3K à Akt1 
pathway is frequently dysregulated in cancer, it is likely that Akt1 plays an 
important role in wound healing and tissue regeneration as well.  
Poly-N-acetyl glucosamine nanofibers (pGlcNAc), a wound healing 
facilitator 
Since the 1970s, increased effort has been directed at searching the ocean and 
its organisms for novel biomolecules.and marine natural products. Marine 
organisms have been a rich source of compounds and several marine products 
are currently in clinical trials for use in treating cancer and infections.  Marine 
natural products exhibit high physiological activity in humans with the most 
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commonly seen activities being their uses as antibiotics, anti-inflammatory, 
antivirals, anticoagulants, analgesics, and antitumorogenic.  These properties 
give marine natural products great potential in the clinical arena for treatment of 
infections, pain, immune diseases, and cancer [125].  Here, I will discuss the 
characteristics of a Poly-N-Acetyl glucosamine nanofiber derived form a marine 
diatom. This nanofiber has proved to be an effective hemostatic agent, but 
currently shows promise as a cutaneous wound healing agent.   
Isolation, Purification, and Characterization 
The pGlcNAc material is a unique polymer structure that is isolated and purified 
from large scale cultures of microalga. The strap like fibers grow from the pores 
of the diatom and are composed of highly crystalline β1à4 poly-N-acetyl 
glucosamine nanofibers.  Studies focused on characterization of pGlcNAc fibers 
used for hemostasis show that the fibers are approximately 100µm in length and 
0.5 µm in width and consist entirely of N-acetyl glucosamine sugar residues 
[126].  Elemental analysis of pGLcNAc confirms the material is composed of 
47.3% Carbon, 6.4% Hydrogen, and 6.9% Nitrogen which is consistent with its 
chemical structure.  Viscosity studies indicate that the average molecular weight 
of the fully acetylated polymer is approximately 2.8 x 106 Da  and consists of 
approximately 50 polysaccharide molecules in which each sugar is N-acetylated 
[126].          
Structural comparison of pGlcNAc and chitosan indicate that pGLcNAc has a 
unique three-dimensional structure that is highly ordered and repetitive compared 
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to the randomly structured chitosan [126].  Structural analysis also shows that 
pGLcNAc fibers are oriented in a parallel fashion and are held together in a 
unique three-dimensional beta crystalline conformation while other polymers 
such as chitin and chitosan are known to exist as random coil polymers [127].  To 
examine the efficacy of pGlcNAc fibers in wound healing, gamma radiation of the 
original pGLcNAG fibers (NAG) was used to shorten the fibers (sNAG) to an 
average length of 4-7 µm and a thickness of 40 – 60nm.  After treatment, the 
polymers maintain their unique three-dimensional structure [128].   
pGlcNAc, a hemostatic agent 
Concentrated efforts have been made in the development of hemostatic agents 
to be used to control bleeding in wounds and during surgical procedures.  The 
development of therapeutic compounds that consist of polymers containing N-
acetyl glucosamine derived from natural sources such as chitins and chitosans 
has increased dramatically in the recent years; however, use of these materials 
is limited by their chemical variability and limited efficacy [127, 129-131].  A newly 
defined polymer, poly-N-acetyl glucosamine (pGlcNAc) was found to be an 
effective hemostatic agent during trauma and surgical procedures [132, 133]. 
When compared to Chitosan based hemostatic products, pGLcNAc nanofibers 
are able to significantly reduce the in vitro fibrin clot formation time of plasma 
samples and has the abiity to cause red blood cell aggregation in vitro [127].  The 
mechanism of action is not fully understood but treated platelets are fully and 
irreversibly activated resulting in the fibrin network formation [134].  Platelet 
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activation by these nanofibers is mediated by the association of pGlcNAc with 
integrin β3 and activation of integrin mediated signaling [135].  
pGlcNAc in Wound Healing 
Recent studies suggests that pure isolations of highly homogenous poly-N-acetyl 
glucosamine nanofibers (pGlcNAc) from a marine diatom may be an excellent 
therapeutic for the treatment of wounds. Treatment of cutaneous wounds with 
pGlcNAc nanofiber-derived membranes results in marked increases in the 
kinetics of wound healing. In a diabetic mouse model where wound closure is 
greatly delayed, pGlcNAc treatment results in a 90% closure, 9 days faster than 
the untreated control [136].  Studies using the shortened, more biodegradable,  
nanofibers showed that sNAG treatment accelerated wound closure in vivo and 
stimulated cell metabolism and migration of endothelial cells and fibroblasts in 
vitro [128].  Treatment with pGlcNAc also induces angiogenesis,  apparently due 
to a direct effect on endothelial cells [137]. pGlcNAc treated wounds also 
exhibited increased vascularity, proliferation, and granulation tissue volume 
during healing. mRNA levels of MMP3 and MMP9, which are related to 
extracellular matrix remodeling in wounded tissue,  are significantly increased 
when diabetic mouse wounds are treated with pGlcNAc [128].  Additionally, 
treatment of cultured primary endothelial cells derived from human umbilical vein 
(EC) in the absence of growth factors or serum, results in increased cell motility 
that is integrin mediated and dependent on the Ets1 transcription factor [137]. 
 




Figure 1.6   Poly-N-Acetyl Glucosamine Nanofibers.  SEM images of marine 
diatom and high molecular weight polysaccharide nanofibers bring extruded from 
pores located at the ends of the cylindrical body.  
Image Credit:  Dr. Tom Fischer, Francis Owens Blood Lab. University of North 








Tissue Culture, Pharmacological Inhibition 
Human umbilical cord vein EC (Lonza) were maintained at 37˚ with 5% CO2 in 
endothelial basal medium 2 (Lonza).  Endothelial basal medium 2 (EBM2) was 
supplemented with EC growth medium 2 SingleQuots as described by Lonza 
procedures and 1% penicillin/streptomycin (Invitrogen).   Serum starvation was 
performed at 80-90% confluency in EBM2 supplemented with 0.1% fetal calf 
serum (Valley Biomedical) for 24 hours followed by stimulation with highly 
purified pGlcNAc (50µg/ml) nanofibers (sNAG) in sterile water (provided by 
Marine Polymer Technologies, Inc., Danvers, Mass., USA). The pGlcNAc diatom-
derived nanofibers used in this study are short biodegradable fibers derived from 
a native, longer form (NAG), and have an average length of 4-7µm and a 
polymer molecular weight of approximately 60,000Da.  For inhibition using 
PD098059 (50µM) or wortmannin (100nM), cells were pre-treated for 45 minutes 
prior to 3 hour stimulation with sNAG (50µg/ml).    
Lentiviral Infection  
	   36	  
Mission shRNA lentiviral constructs directed against Akt1 were purchased from 
Sigma/Aldrich. A scrambled pLKO.1 shRNA vector was purchased from Addgene. 
Lentiviruses were propagated in 293T cells, maintained in DMEM supplemented 
as above. Lentiviral production was performed using psPAX2 and pMD2.G 
packaging vectors purchased from Addgene using the protocol for producing 
lentiviral particles from Addgene. For infection of target cells, 7.5 X 105 cells were 
plated on 100 mm2 plates and allowed to incubate overnight.  The next day, cells 
were transduced using a final concentration of 1 µg/ml polybrene and either 
scrambled control or Akt1 shRNA lentiviruses. After transduction, endothelial cells 
were serum starved overnight and stimulated with sNAG (50g/ml) for 3 hours.  All 
infections were monitored for appropriate knockdown by RT-PCR.  
RT-PCR 
For semi-quantitative RT-PCR, RNA was extracted with RNAsol (Teltest, Inc.) 
following manufacturer’s instructions.  cDNA was synthesized from 2 µg total 
RNA with a Superscript First Strand Synthesis Kit (Invitrogen), using Oligo(dT) 
following the manufacturer’s instructions.  PCR reactions contained equal 
amounts of cDNA and 1.25 µM of the appropriate primer pair (Sigma-Proligo, St. 
Louis, MO, USA).   All primer sequences used in these analyses are as follows:  
Akt1 F 5’ GAGGCCGTCAGCCACAGTCTG 3’ 
Akt1 R 5’ ATGAGCGACGTGGCTATTGTG 3’ 
β-Defensin3 F 5’ GTGGGGTGAAGCCTAGCAG 3’ 
β-Defensin 3 R 5’ TTTCTTTCTTCGGCAGCATT 3’ 
α-Defensin1 F 5’ CACTCCAGGCAAGAGCTGAT 3’ 
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α-Defensin1 R 5’ TCCCTGGTAGATGCAGGTTC 3’ 
S26 F 5’ CTCCGGTCCGTGCCTCCAAG 3’ 
S26 R 5’CAGAGAATAGCCTGTCTTCAG 3’ 
 
 Cycling conditions were: 94°C for 5 min; 30-35 cycles of 94°C for 1 min, 
55-65°C (based on primer Tm) for 1 min, 72°C for 1 min; 72°C for 7 min and 
cooled to 4°C.  Cycle number was empirically determined to be within the linear 
range of the assay for each primer pair used. All semi-quantitative RT-PCR was 
performed with the ribosomal protein subunit S26 primers as internal controls.  
Products were visualized on a BioRad Molecular Imaging System (Hercules, CA, 
USA).  Real time PCR was performed using a Brilliant CYBR green QPCR kit in 
combination with an Mx3000P Real-Time PCR system both purchased from 
Stratagene.  Primers detecting the ribosomal subunit S26 were used as internal 
controls. 
PCR analysis of Tissue 
For semi-quantitative RT-PCR cDNA was synthesized from total RNA (2-5µg), 
isolated from 5 day post wound tissue (treated and untreated) using RNA-STAT 
60 (Tel-Test, Inc.) in procedures described by the manufacturer, with a 
Superscript First Strand Synthesis Kit purchased from Gibco BRL using 
Oligo(dT) following the manufacturer’s instructions.  PCR reactions contained 
equal amounts of cDNA and 1.25µM of the appropriate primer pair (IDT, Inc.).  
The primer sequences are as follows: Collagen I: forward 5’ 
ACGGCTGCACGAGTCACAC 3’, reverse 5’ GGCAGGCGGGAGGTCTT  3’, 
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Collagen III: forward 5’ GTTCTAGAGGATGGCTGTACTAAACACA 3’, reverse 5’ 
TTGCCTTGCGTGTTTGATATTC  3’ and HPRT: forward 5’ 
AAGGACCTCTCGAAGT 
GTTGGATA 3’ reverse 5’ CATTTAAAAGGAACTGTTGACAACG 3’.  Cycling 
conditions were: 94°C for 5 min; 20-35 cycles of 94°C for 1min, 50-65°C (based 
on primer Tm) for 1min, 72°C for 1min 45sec + 2sec/cycle; 72°C for 7min and 
cooled to 4°C.  Cycle number was empirically determined to be within the linear 
range of the assay for each primer pair used. All semi-quantitative RT-PCR was 
performed in tandem with HPRT primers as an internal control.   
Excisional Wound Healing Model 
Wild Type C57Bl/6 and Akt1-/- [138] were used in all experiments.  The Akt1 null 
animals were created using an insertional mutagenesis strategy at the 
translational start site that blocks expression of the entire protein. All experiments 
performed using mice were in accordance with animal procedure protocols 
approved by the Medical University of South Carolina Institutional Animal Care 
and Use Committee.  Wounding was performed on anesthetized adult male mice 
between 8-12 weeks old. Two full thickness cutaneous wounds were created 
using a 4mm biopsy punch (Miltex), to create two identical wounds on each flank. 
Mice were anesthetized using an O2/Isoflurane vaporizing anesthesia machine 
(VetEquip, Inc.).  Isoflurane was used at 4% for induction; 2% for surgery. Prior 
to surgery hair was removed by depilation and the area was washed and 
sterilized using 70% ethanol.   Wounds were either treated with sNAG membrane 
moistened with distilled water or left untreated.  On days 3 and 5 animals were 
	   39	  
euthanized and entire wounds were harvested including the surrounding skin 
using an 8mm biopsy punch (Miltex).  Wounds were fixed in 4% 
paraformaldehyde overnight at 4˚, embedded in paraffin, and sectioned for 
analysis. 
Hematoxylin and Eosin Staining (H&E) 
All H&E staining was performed in the Histology Core Facility at the Medical 
University of South Carolina, Department of Regenerative Medicine and Cell 
Biology.  Briefly, sections were cleared in xylene, rehydrated through a series of 
graded alcohols, placed in Hematoxylin followed by acid alcohol.  Samples were 
then placed in ammonia water, rinsed in ethanol and exposed to Eosin before 
dehydrating through graded alcohols and clearing in xylene.  Sections were 
mounted using Cytoseal-XYL (Richard-Allan Scientific).  H&E sections were 
visualized using an Olympus BX40 microscope (4x objective lens, 0.13) and 
captured using an Olympus Camera (Model DP25) and DP2-BSW acquisition 
software.   
Bacterial Inoculation, Tissue Gram Staining, Colony Forming Unit 
Quantitation 
Male mice between 8-12 weeks were wounded as described above.  Single 
colonies of Staphylococcus aureus (ATCC 25923) were picked and cultured 
overnight at 37˚ and adjusted to an absorbance of OD600= 0.53.  One mL of S. 
aureus was spun at 10,000rpm, re-suspended in sterile PBS, and 15µl was used 
to innoculate each wound.  sNAG membranes were applied to the treated group 
thirty minutes post inoculation.  Mice were euthanized on day 3 and 5 post 
wounding and wounds were harvested using an 8mm biopsy punch.  One wound 
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per animal was fixed overnight in 4% paraformaldehyde at 4˚C and the other 
wound was cultured and plated on LB media without antibiotic for bacterial 
quantitation (see below).  Wounds for tissue gram staining were embedded in 
paraffin and sectioned.  Sections were cleared in xylene and rehydrated through 
a series of alcohol and were stained using a tissue gram stain (Sigma-Aldrich) by 
procedures described by the manufacturer.   
For culturing, wound sections were placed in 0.5ml bacterial media an incubated 
for 30 min at 37oC while shaking. Colony forming units (CFU) were quantitated 
using a dilution series plated overnight at 37˚C.  Number of colonies per plate/per 
dilution were counted and CFU/ml were calculated.   To determine CFU/ml from 
sNAG treated bacterial cultures, S. aureus cultures in solution were treated with 
varying concentrations of sNAG for three hours.  Cultures were then plated 
overnight at 37˚ and CFU/ml were determined.   
β-defensin 3 Peptide Application 
 Three test concentrations (1.0µM, 2.5µM, 5.0µM) of biologically active human β-
defensin 3 peptide (Peptide Institute, Inc.) were tested for their effect on bacterial 
growth in the infected wound healing model described above. Each concentration 
negatively affected bacterial growth so the lowest concentration was chosen for 
analyses. After each wound was infected with S. aureus, 10ul of peptide was 
applied.  After three days, wounds were harvested, embedded for sectioning and 
gram staining, or cultured for CFU/ml quantitation as described above.  
β-defensin 3 Antibody Blockade 
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 Wild Type male mice were wounded and infected with 15ul of S. aureus 
as described above.  After inoculation, one wound was treated with 0.2ug/mL of 
β-defensin 3 antibody (Santa Cruz) while the other was treated with 0.2ug/mL of 
normal goat IgG control antibody (Santz Cruz).  sNAG membranes were applied 
to all mice after antibody treatment on day 0. Antibody was applied every 24 
hours.  Mice were euthanized on day 3 and wounds were harvested using an 
8mm biopsy punch.  Wounds were fixed overnight in 4% paraformaldehyde at 
4˚C, embedded in paraffin, sectioned, and analyzed using tissue gram stain.   
Immunofluoresence, Microscopy 
Paraffin embedded tissue sections were re-hydrated through xylene and a series 
of graded alcohols.  Sections were treated with 0.01% Triton-X100 and subjected 
to antigen retrieval using antigen unmasking solution (Vector Laboratories) in a 
pressure cooker for 5min and allowed to cool.  Sections were incubated in 
background buster (innovex Biosciences) for 30 minutes prior to antibody testing. 
Skin sections were labeled with β-defensin 3 goat polyclonal antibody (Santa 
Cruz), involucrin rabbit polyclonal antibody (Santa Cruz),  TO-PRO 3-iodide 
(Molecular Probes), mouse monoclonal anti-Actin α-Smooth Muscle antibody 
(Sigma),  Vimentin mouse monoclonal antibody (Dako), Phalloidin (Molecular 
Probes) and DAPI (Molecular Probes). Sections were incubated in primary 
antibody overnight at 4˚ and appropriate secondary immunofluorescent 
antibodies (Invitrogen) for 1 hour at room temperature.  Control sections for each 
antibody were stained without primary antibody.   Tissue sections were visualized 
using an Olympus FluroView laser scanning confocal microscope (Model IX70) 
	   42	  
and captured at ambient temperature using an Olympus camera (Model FV5-ZM) 
and Fluoview 5.0 acquisition software.  All tissue sections were imaged using 60x 
oil immersion lens (Olympus Immersion Oil) 
HUVECs were either serum starved or treated with sNAG for 5 hours in culture 
and stained with antibodies directed against α-defensin 5 (FITC), β-defensin 3 
(Texas Red), or TOPRO 3 (Blue).  Images were taken using immunofluorescent 
microscopy.  Cell culture defensin expression was visualized using a Zeiss 
Axiovert 100M confocal microscope and was captured at ambient temperature, 
using water as the medium, using LSM 510 camera (Zeiss Fluor 63xW/1.2A 
objective).   
Western Blot Analysis 
Endothelial cells were serum starved prior to stimulation with sNAG (50µl/ml) for 
a given time course.  Cells were then lysed and subjected to Western blot 
analysis.  The antibodies used for Western blot analysis are as follows: anti-p85 
subunit of PI3K and phosphospecific Akt antibody (Cell Signaling Technologies). 
Scar Quantification, Tensile Strength Measurements, Elasticity 
Measurements 
For scar measurements, wild type mice were wounded as previously described 
and allowed to heal for 21 days. On day 21, animals were euthanized and scars 
were measured using a caliper.   
For tensile strength, wounded animals were sacrificed after 21 days, wounds 
were harvested and skin was trimmed (15mm x 7mm) to insure even tension.  
Wounds, both treated and untreated and unwounded control skin was subjected 
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to tensile strength and elasticity testing using an Instron 5942 strain gauge 
extensometer and Bluehill 3 Testing Software.  Tensile strength of the skin was 
determined by measuring the relative stress the skin could bear before breaking 
20% and elasticity was measured as the mm of extension.   
Masson Trichrome Staining, Picro Sirius Red Staining 
Masson’s Trichrome stain (Sigma-Aldrich) was performed according to 
manufacturer’s instructions for tissue sections. Briefly, sections were 
deparrafanized to water and incubated in Bouin’s solution. Slides were subjected 
to a series of incubations using hematoxylin, Biebrich Scarlet-Acid Fucshin, 
Phosphotungstic/Phosphomolybdic acid solution, Aniline Blue solution, and 
Acetic Acid as described by the manufacturer tissue sections were then 
dehydrated, cleared in xylene, and mounted using Cytoseal-XYL (Richard-Allan 
Scientific).  Masson’s trichrome sections were visualized using an Olympus BX40 
microscope and images were captured using an Olympus Camera (Model DP25) 
and DP2-BSW acquisition software.   
For Picro Sirius Red Staining, tissue sections were fixed stained in iron 
hematoxylin for 10 minutes followed by a 10-minute rinse in running water.  
Slides were placed in PSR (Sigma, St. Louis, MO) for 1-hour, followed by three 
5-minute rinses in 1% acetic acid. Tissue sections were dehydrated prior to 
mounting. PSR staining was viewed under polarized light to distinguish mature, 
thick collagen fibers (red/orange) from the immature, thin collagen fibers 
(green/yellow) due to their intrinsic birefringence.  
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Extraction and Biochemical Quantitation of Collagen 
Hydroxyproline assays were performed as previously described [139].  Briefly, 
wound tissue was harvested from wild type mice treated or untreated at 21 days 
post wounding (n=4 for each). Tissue was lyophilized and weighed to ascertain 
dry weights and finely ground. Tissue collagen underwent complete acid 
hydrolysis with 6 N HCl for 18 h at 120°C, and neutralized to pH 7 with 4 N 
NaOH. One milliliter of chloramine T was added to 2-ml volumes of the collagen 
sample and incubated at room temperature for 20 min. One milliliter of Ehrlich's 
reagent (60% perchloric acid, 15 ml 1-propanol, and 3.75 g p-dimethyl-amino-
benzaldehyde in 25 ml) was added, and samples were incubated at 60°C for 20 
min. Absorbance at a wavelength of 558 was read on a spectrophotometer. 
Collagen was quantified as milligrams of hydroxyproline per gram dry weight of 
the wound tissue. 
Elastin Staining 
Tissue sections from wounded animals, as described above, were stained for 
elastin fibers using Van Geison staining procedures ().  Briefly, sections were 
cleared in xylene, rehydrated through a series of graded alcohols to distilled 
water, stained in hematoxylin (Sigma-Aldrich), differentiated in 2% ferric chloride 
and washed.  Tissue sections were then stained in Van Geison’s counterstain 
prior to dehydration, clearing in xylene, and mounting with Cytoseal-XYL 
(Richard-Allan Scientific).  Tissue sections were sections were visualized using 
an Olympus BX40 microscope and captured using an Olympus Camera (Model 
DP25) and DP2-BSW acquisition software.   
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Tissue Culture, Fibrin Gel Assay 
C3H10 Fibroblasts were maintained at 37°C with 5% CO2 in minimal essential 
medium with Earle’s balanced salt solution (MEM/EBSS, Thermo) supplemented 
with 1% penicillin/streptomycin (Invitrogen). Normal human fibroblasts (ATCC) 
were maintained in MEM supplemented with 20% FCS. Serum starvation was 
performed at 80–90% confluency in MEM/EBSS supplemented with 0.1% fetal 
calf serum (Valley Biomedical) for 24 hours followed by stimulation with highly 
purified pGlcNAc (50 µg/ml) nanofiber slurry (sNAG) in sterile water (provided by 
Marine Polymer Technologies, Inc.).  
Fibrin Gel Assays were performed in 24 well tissue culture plates (Becton 
Dickinson). Plates were prepared for procedure by addition of 300 ml Sylgard 
184 elastomer (Dow Corning) to the bottom of the well, which was allowed to set 
overnight at 37°C with 5% CO2. Two 0.1 mm minutien pins (Fine Science Tools) 
were inserted into the Sylgard along the (16mm) diameter of the well bottom, 
3mm away from each edge. Wells were blocked with 3% BSA in PBS for 30 
minutes.  Cells were counted and resuspended  in a fibrinogen solution 
composed of 5% human fibrinogen (Sigma) dissolved in cold MEM/EBSS media 
with the addition of 10µl/ml ascorbate and plated at a concentration of 250,000 
cells per well. Thrombin (100units/mL) from human plasma (Sigma) was added 
to 5mg/mL fibrinogen and cell solution. The gels were incubated for 30 minutes 
at 37° with 5% CO2 prior to the addition of 1 ml of MEM/EBSS supplemented 
with 5% fetal calf serum. A small pipette tip was used to gently detach gels from 
the well walls. Gels were then monitored for contraction over time. When 
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contraction was sufficient, the media was removed, and the gels were washed 3 
times with PBS for 5 minutes each and fixed with 4% paraformaldehyde for 30 
minutes prior to either embedding in paraffin for tissue analysis or for phalloidin 
staining.  For phalloidin staining: fibrin gels were treated with 0.3% Triton-X100 
and incubated in phalloidin for 1 hour at room temperature, and counter-stained 
with DAPI for 10 minutes. Sections were mounted using fluorogel. For tissue 





Wound infection is a major complication especially in patients with chronic 
disease such as diabetes or during immunosuppression. Such patients have 
disruptions in appropriate inflammatory responses, including the migration and 
recruitment of neutrophils and macrophage, which predisposes them to 
increased infection [2]. In addition, bacterial infection can lead to impairment of 
wound healing and sepsis. Given the ineffectiveness of many current antibiotic 
treatments and the increased prevalence of antibiotic resistant bacteria such as 
MRSA (Methycillin-resistant S. aureus), new clinical treatments are in high 
demand. 
Our published data shows that treatment of primary endothelial cells with sNAG 
results in an increased cell migration, which is due to an integrin-dependent up-
regulation of the Ets1 transcription factor. Ets1 regulates numerous processes 
such as immune function and embryonic development by the transcriptional 
regulation of genes involved in cell migration, proliferation and survival. Indeed, 
sNAG stimulation of endothelial cells results in the increased expression of 
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several cytokines and growth factors such as IL-1 and VEGF that are imperative 
for proper wound healing [137]. 
Given that sNAG stimulation results in increased secretion of cytokines important 
for immune function [137]; we sought to determine if sNAG treatment would 
result in increased expression of defensins and would therefore have 
antibacterial activity in addition to its wound healing activities. In this chapter, 
both use both in vitro and in vivo models to determine the effect of sNAG 
treatment on defensing expression.   
Keratinocytes and endothelial cells express and secrete defensins when 
stimulated with sNAG  
To investigate the affect of sNAG treatment on defensin expression in vitro, 
primary human umbilical vein endothelial cells in culture were used. As shown in 
Figure 3.1 A endothelial cells treated with sNAG show an up-regulation of β-
defensin 3 and α-defensin 1 mRNA expression within 1 hour of stimulation.  
Similar upregualtion of α-defensin 4 and 5 by sNAG treatment was also observed 
(data not shown).  Custom gene arrays containing over 25 different defensin 
genes were used to confirm the expression of the α-type defensins in primary 
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endothelial cells and the β-type defensins in keratinocytes.  sNAG stimulation of 
endothelial cells was shown to increase the expression specifically of α-defensins 
1, 4 and 5 and β-defensin 3.   Additionally, sNAG stimulation of human 
keratinocytes increased expression of β-defensin like genes, several of which are 
listed in Table 3.1.  These findings suggest that at least three α-defensin genes 
and β-defensin 3 are expressed in primary endothelial cells and multiple β-
defensin genes are expressed in primary keratinocytes in response to sNAG 
stimulation.  
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Figure 3.1  sNAG treatment results in expression and secretion of 
defensins in vitro. 
 
 
	   51	  
 
Figure 3.1  sNAG treatment results in expression and secretion of 
defensins in vitro.  (A) RTPCR analysis of serum starved (SS) primary 
endothelial cells treated with sNAG (50µg/ml) for the times indicated and 
assessed for expression of β-defensin 3 and α-defensin 1. (B) 
Immunofluorescent labeling of endothelial cells either serum starved (untreated) 
or treated with sNAG nanofibers (10µg/ml for 5hrs).  Antibodies are directed 
against α-defensin 5 (Green, FITC), β-defensin 3 (Red, Texas Red).  Nuclei are 
stained with TOPRO-3 (Blue).  Lower right hand corner represents triple overlay.  
(C)  Immunofluorescent labeling of keratinocytes (HaCat) that are either serum 
starved (untreated) or treated with sNAG nanofibers (10µg/ml for 5 hours). 
Antibodies are directed against α-defensin 5 (Green, FITC), β-defensin 3 (Red).  
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Table 3.1 Table demonstrating the fold change detected in expression of specific 
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To test whether the sNAG-dependent defensin expression also occurred on the 
protein level, sNAG stimulated endothelial cells were subjected to 
immunofluorescence using antibodies directed against both α and β defensins. As 
shown in Figure 3.1B, both β-defensin 3 and α-defensin 5 are up-regulated upon 
sNAG stimulation in this cell type. However, stimulation of primary human 
keratinocytes (HaCat) with sNAG did not cause increased expression of α-
defensin but does cause an increase in the expression of β-defensin 3 (Fig 3.1C).  
Taken together, these experiments suggest that sNAG stimulation results in an 
up-regulation of defensin peptides in both primary keratinocytes and primary 
endothelial cells. 
sNAG-dependent defensin expression requires Akt1 
Previously published data show that sNAG stimulation of primary endothelial cells 
results in increased integrin activation, Ets1 expression and MAP kinase 
activation [137]. Findings from our laboratory position Akt1 upstream of Ets1 in 
endothelial cells and in Drosophila [122].  To begin to determine the signaling 
pathway responsible for the expression of defensins, endothelial cells were serum 
starved and pre-treated with pharmacological inhibitors directed against PI3K 
(wortmannin) or MAP kinase (PD098059) prior to sNAG stimulation. Quantitative 
real time PCR analysis shows that α-defensin 1 mRNA levels are greatly 
diminished after inhibition of either the PI3K/Akt pathway or the MAP kinase 
pathway (Fig 3.2A).  RT-PCR analysis of β-defensin 3 also shows that levels are 
decreased by the inhibition of these pathways as well (Fig 3.2B).  sNAG 
treatment of endothelial cells for a short time course leads to phosphorylation of 
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Akt1, a standard indicator of its activation (Fig 3.2C).  To confirm that Akt1 is 
indeed required for defensin expression, lentiviral delivery of shRNA directed 
against Akt1 was used.  Quantitative RT-PCR of serum starved endothelial cells 
infected with scrambled (SCR) control or Akt1 shRNA followed with sNAG 
treatment confirms that Akt1 expression is required for sNAG-dependent α-
defensin expression (Fig 3.2D).  Since β-defensins are known to be expressed in 
epithelial cells, lentiviral delivery of shRNA directed against Akt1 was used in 
human keratinocytes (HaCat).  sNAG treatment of serum starved keratinocytes 
infected with scrambled (SCR) control leads to a significant increase in β-defensin 
3 expression that is abrogated by Akt1 knockdown (Fig 3.2E). These results 
illustrate that sNAG treatment activates Akt1 in endothelial cells and strongly 
suggest that sNAG-dependent defensin expression requires Akt1 in both 
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Figure 3.2 (A-B).  sNAG induced defensin expression is dependent on Akt1.  
(A) Quantitative RT-PCR analyses using primers directed against α-defensin 1 
from total RNA isolated from serum starved endothelial cells treated with or 
without sNAG for 3 hours, with or without pretreatment with PD098059 (50µM), 
wortmannin (100nm). Quantitation is relative to the S26 rprotein subunit.  (B) 
Quantitation of β-defensin 3 expression from total RNA isolated from serum 
starved endothelial cells treated with or without sNAG for 3 hours, with or without 
PD98059 (50µm), wortmannin (100nm) and shown as relative to S26. 
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Figure 3.2 (C-E) sNAG induced defensin expression is dependent on Akt1.   
(C) Western Blot analysis of phospho-Akt in serum starved endothelial cells (SS) 
stimulated with sNAG for the times indicated. Line indicates where lanes have 
been removed  (D) Quantitative RT-PCR analyses of serum starved endothelial 
cells infected with a scrambled control (SCR) or Akt1 shRNA lentiviruses, treated 
with or without sNAG and assessed for α-defensin 4 expression.  Quantitation is 
shown relative to S26. (E) Quantitation of β-defensin 3 expression from total RNA 
isolated from serum starved endothelial cells infected with a scrambled control 
(SCR) or Akt1 shRNA lentiviruses, treated with or without sNAG. Quantitation is 
shown relative to S26. All experiments were done in at least triplicate and 
repeated at least three independent times and p values are shown.   
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sNAG treatment of cutaneous wounds increase defensin expression in vivo  
To confirm the dependence of Akt1 for the expression of defensins in vivo, wild 
type and Akt1 null animals were used in an excisional wound healing model. 
Although most mammalian leukocytes express α-defensins (human, rabbit, rat, 
and hamster), mouse leukocytes do not express α-defensins.  We therefore 
focused on β-defensin expression in these mouse models.  Treatment of 
cutaneous wounds with a dried form of sNAG, a thin biodegradable membrane, 
for three days results in a statistically significant increase in β-defensin 3 
expression in keratinocytes of wild type animals (Fig 3.3A).  Involucrin [140] 
staining (red) was used to mark the keratinocyte cell layers and show that the 
expression of β-defensin 3 is confined to the epidermal layer. To assess if sNAG-
dependent defensin expression is dependent on Akt1, a similar assay was 
performed using an Akt1 null animal model.  Wounds from Akt1 null mice treated 
with sNAG membranes show a markedly reduced induction of β-defensin 3 
expression (Fig 3.3A).  To better visualize the epidermal layers that are 
expressing β-defensin 3, Figure 3.3B shows a representative image of a sNAG 
treated wild type wound harvested on day 3.  sNAG treatment of cutaneous 
wounds induced β-defensin 3 expression mainly  in the suprabasal layers of skin 
(Fig 3.3B).  Quantitative analyses shown in Figure 3.3C shows an approximate 5-
fold increase in β-defensin 3 expression in sNAG treated wild type animals and 
that Akt1 is required for this increase.   
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Figure 3.3.    
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Figure 3.3  sNAG induced defensin expression in vivo requires Akt1.  (A) 
Paraffin embedded sections of cutaneous wounds harvested on day 3 post 
wounding from both WT (n=3) and Akt1 mice. Wounds were either untreated or 
treated with sNAG membrane. Immunofluorescence was performed using 
antibodies directed against β-defensin 3 (green), Involucrin (Red), and Topro 
(Blue). (B) Paraffin embedded section from WT treated with sNAG harvested on 
day 3. Immunofluorescence was performed using antibodies directed against β-
defensin 3 (green), Involucrin (Red), and Topro (Blue). This lower magnification 
(20x) is included to better illustrate the epidermal layers expressing β-defensin 3. 
Scale bars = 50 μm. (C) Quantitation of β-defensin 3 expression from paraffin 
embedded sections was performed using NIH ImageJ software.  Experiments 
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sNAG treatment increases the kinetics of wound closure in WT animals.   
 Previous results have shown an increased kinetics of wound closure in 
diabetic mouse models in response to sNAG treatment. We tested whether sNAG 
had a similar affect in wild type animals. Excisional wounds were created in wild 
type animals which were either treated with the membrane form of sNAG or left 
untreated. Tissue sections were taken at 1, 3 and 5 days post wounding and 
subjected to H&E staining. As shown in Figure 3.4, sNAG treatment of wild type 
wounds results in complete closure, as visualized by the solid line, at day 3 post 
wounding. This occurs two days earlier than in the control wounds. Akt1 null 
animals display a delay in wound closure; these animals do not fully close the 
wound until 7 days post wounding.  The delay in wound closure in the Akt1 null 
animals is not rescued by sNAG treatment. These findings suggest that sNAG not 
only induces defensin expression but also increases wound healing kinetics in 
wild type mice and may be a novel and effective therapeutic.   
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Figure 3.4 sNAG treatment increases wound closure in wild type mice (A) 
H&E staining of wound tissue sections derived from C57Bl6 wild type animals 
either untreated or treated with sNAG membrane. The day post-wound is 
indicated to the left of each panel. The solid black line follows the keratinocyte cell 
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 sNAG is an effective antimicrobial against S. aureus 
It is well known that defensins are members of a large family of antimicrobial 
peptides.   Since the treatment of endothelial cells with sNAG increases defensin 
expression (both α- and β-type) and that treatment of cutaneous wounds with 
sNAG dramatically increases β-defensin 3 expression in vivo, we next assessed 
the antimicrobial efficacy of sNAG treatment in bacterially infected wounds.  Wild 
type and Akt1 null animals were subjected to cutaneous wounding, followed by 
infection with Staphylococcus aureus. Infected wounds were either treated with 
sNAG or left untreated for 3 and 5 days post infection. As shown by the tissue 
gram staining in Figure 3.5A, wild type animals treated with sNAG show a 
significant reduction in gram positive staining by day 5 post wounding as 
compared with untreated wounds. In contrast, gram stained tissue derived from 
untreated wounds in Akt1 null animals at 5 days post wounding show an 
accumulation of neutrophils which stain gram positive, indicating a potential lack 
of bacterial clearance in these animals that is not rescued by sNAG treatment. 
These findings suggest that Akt1 null animals have a defect in immune clearance 
mechanisms which is not rescued by sNAG treatment. 
 To quantitate sNAG-specific bacterial changes in colony forming units (CFU), 
infected wounds from both wild type and Akt1 null mice either sNAG treated or 
untreated were harvested and cultured.  As shown in Figure 3.5B, at 5 days post 
wounding bacterial number is markedly reduced (10-fold) in wild type animals 
treated with sNAG. However, although the number of bacteria detected in the 
Akt1 null animals is reduced in comparison to wild type, sNAG treatment had a 
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little effect on absolute bacterial number in the Akt1 null animals.   At 3 days 
post-infection (Fig. 3.5C), there is a similar 10-fold decrease in CFU in sNAG 
treated wild type mice as compared to untreated controls. The sNAG treated 
Akt1 null animals show a 2-fold decrease in CFU as compared to untreated Akt1 
null animals. In general, the Akt1 null animals have a lower bacterial load per 
wound which may be reflective of an Akt1-dependent effect on other processes 
in addition to defensin expression. These findings suggest that sNAG treatment 
results in a marked reduction in bacterial load in infected cutaneous wounds in 
wild type mice but not in Akt1 null mice, suggesting the possibility that defensins 
are mediating the anti-bacterial response. To show that the antibacterial effect of 
sNAG treatment is not due to a direct effect of the nanofibers on bacterial growth 
or on their survival, S. aureus bacterial cultures were treated in solution with 
different amounts of sNAG, for 3 hours and colony forming units were determined.  
As shown in Figure 3.5D, sNAG treatment had no direct effect on the growth of 
S. aureus, indicating that sNAG is not directly inhibiting bacterial growth and may 
then be working via the up-regulation of defensins. 
Application of defensin peptide mimics the sNAG antibacterial effect  
To determine whether addition of defensin peptide can block bacterial infection 
similarly to that shown for sNAG treatment, wild type mice were wounded and 
inoculated with S. aureus as described above and then treated with biologically 
active human β-defensin 3 peptide (1.0µm) for three days. Tissue biopsies were 
stained using a tissue gram stain and CFU was quantitated. Figure 3. 5E-5F 
shows the results of these experiments. Infected mice treated with β-defensin 3 
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peptide have a decreased bacterial load, an approximate 7.5 fold decrease in 
viable bacteria (Fig. 3.5F), similar to that shown in wild type mice treated with 
sNAG.   
One of the mechanisms by which defensin expression is induced is through 
stimulation by bacterial LPS, possibly through the activation of Toll like receptors 
[88]. To test whether bacterial infection alone is able to induce β-defensin 
expression within the time periods tested, expression of β-defensin was assessed 
in infected wounds from wild type animals after three days post wounding. As 
shown in Figure 3.6A, bacterial infection alone does not induce the expression of 
β-defensin within 3 days of infection, as is shown with sNAG treatment. However, 
in wild type animals, sNAG treatment of infected wounds causes approximate 3- 
to 5-fold increase in the expression of β-defensin within a similar time period (Fig. 
3.6B). These findings suggest that sNAG treatment rapidly induces the 
expression of defensin expression resulting in marked bacterial clearance in S. 
aureus infected wounds.  
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Figure 3.5.  sNAG treatment reduces bacterial infection in an Akt1 
dependent manner.  (A) Tissue gram staining of paraffin embedded S. aureus 
infected wounds from WT and Akt1null mice (n=3).  Infected wounds were either 
untreated or treated with sNAG membrane and wound beds were harvested on 
day 3 and day 5 for analysis. Dark purple staining indicates the presence of gram 
positive bacteria in the wound bed.  Black arrows indicate examples of gram 
positive staining. Note the accumulation of positive staining in untreated WT that 
is lacking in WT animals treated with sNAG.   Scale bars = 50μm. (B) CFUs 
derived from day 5 post wounding were quantitated from S. aureus infected 
wounds using both treated and untreated WT (n= 3) and Akt1 mice (n=3). Wild 
type mice that were sNAG treated show a significant (p<.01) decrease in bacteria 
load in the wound beds as compared to Akt1 null animals.  All experiments were 
repeated three independent times and the p values are shown. (C)  CFU 
quantitated from infected wounds at day 3 post wounding in a similar fashion 
described in (B). sNAG treatment of infected wounds shows a significant 
decrease in CFU of both WT and Akt1 null animals on day 3, but the WT animals 
show an approximate 10 fold difference compared to a 2 fold difference in Akt1 
animals.  (D) Quantitation of CFUs in S. aureus cultures that were either 
untreated or treated with various amounts of sNAG nanofibers.   Each 
experiment was performed three independent times and p values are shown.  (E) 
Tissue gram staining of S. aureus infected wounds harvested on day 3 post 
wound from WT mice (n=3) that were treated with or without β-defensin 3 peptide. 
Note the decrease in gram positive staining in infected wounds that were treated 
	   67	  
with β-defensin 3 peptide.   (F) Quantitation of CFUs from S. aureus infected WT 
mice (n=3) treated with or without β-defensin 3 peptide. Infected wounds that 
were treated with peptide show a significant decrease (p <.05) in CFU.  Scale 
bars = 50μm.  Each experiment was performed three independent times and p 
values are shown 
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Figure 3.6.  Rapid induction of defensin expression by sNAG treatment of S. 
aureus infected wounds.  (A) Paraffin embedded tissue sections from S. 
aureus infected wounds, harvested on day 3, were subjected to 
immunofluorescence using antibodies directed against  β-defensin 3 (green), 
Involucrin (red) to mark the keratinocyte layer, and Topro (blue) from both sNAG 
treated WT (n=3) and untreated WT mice (n=3). Non specific staining of keratin 
is indicated by the no primary control which was stained with secondary antibody 
only.  Scale bar = 50μm. (B) Quantitation of β-defensin 3 expression from 
paraffin embedded sections using NIH ImageJ software.  S. aureus infected 
wounds that were treated with sNAG show a significant increase (p<.05) in β-
defensin 3 staining. Experiments were repeated three independent times and p 
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Antibodies directed against β-defensin 3 block the antibacterial effect of 
sNAG 
 Since defensins are secreted proteins, we reasoned that antibodies 
directed against β-defensin 3 may be able to block the antibacterial activities. To 
test this hypothesis, wounds were created, infected with S. aureus and treated 
with sNAG as described above. The wounds were either treated with a β-defensin 
3 antibody or an isotype control; one application each day for three days. Wound 
sections were obtained and stained for gram positive bacteria. As shown in 
Figure 3.7A, sections derived from wounds treated with β-defensin antibody have 
more gram positive bacteria than those treated with isotype control antibodies. 
Each section shown was derived from the wound area directly under the scab.  
Quantitation of CFU in these wounds shows that neutralization of β-defensin 3 
prior to sNAG treatment in S. aureus infected wounds results in a significant 
increase in bacteria. Animals that were treated with an IgG isotype control show 
an approximate 5-fold reduction in viable bacteria (Fig 3.7B).  Taken together, our 
results suggest that sNAG treatment not only results in the increased kinetics of 
wound healing but also promotes an endogenous anti-bacterial response and 
supports the use of this nanofiber as novel therapy to enhance wound healing 
while concurrently decreasing wound infection. 
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Figure 3.7  Antibodies against β-defensin 3 impedes antibacterial effects of 
sNAG treatment.  (A) Tissue gram staining of paraffin embedded S. aureus 
infected wounds treated with sNAG from WT mice (n=3) that were harvested on 
Day 3.   sNAG treated wounds were treated with either β-defensin 3 antibody or 
isotype control goat IgG antibody prior to sNAG treatment. Representative 
images show increased accumulation gram positive staining (black arrows) in the 
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wound beds  of mice treated with an antibody directed against β-defensin 3. 
Scale bar = 20μm. (B)  Quantitation of CFUs from S. aureus infected WT mice 
treated either β-defensin 3 antibody (n=3) or control IgG antibody (n=3) prior to 
sNAG treatment. β-defensin 3 application significantly increasedd (p <.05) CFU.   
 
Discussion 
The findings presented here suggest the use of a marine diatom derived 
nanofiber, sNAG as a novel and effective method to enhance wound healing 
while concurrently decreasing wound infection. We show that this FDA approved 
material presently used for hemostasis, stimulates the expression of both α-type 
and β-type defensins in primary endothelial cells and an up-regulation of the β-
type in primary keratinocytes. We also show both in vitro and in vivo that Akt1 is 
required for defensin expression. sNAG treatment decreases Staph aureus 
infection of cutaneous wounds in wild type control animals but not in similarly 
treated Akt1 null animals. It is also important to note that sNAG stimulation of 
wild type cutaneous wounds results in an increased kinetics of wound closure.  
Antibody blockade of β-defensin results in a reduction in the sNAG-antibacterial 
activity. Taken together our findings suggest a central role for Akt1 in the 
regulation of defensin expression that is responsible for the clearance of bacterial 
infection and that sNAG treatment activates these pathways in wild type animals.  
We present data that suggests that sNAG treatment of infected wounds could 
drastically decrease bacterial load in patients, at least in part, by the induction of 
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defensin expression. Control experiments indicate that the antibacterial effect of 
sNAG is not due to a direct interaction of the material with the bacteria but is due 
to downstream affects such as the regulation of defensins by Akt1 activation. It is 
widely accepted that defensins are important players in innate immunity and 
function in antimicrobial activities. Most of the evidence for their function is the 
direct killing of bacteria by in vitro mixing experiments with purified defensin 
peptides [88] or in similar experiments as shown in Figure 3.5 with direct 
application of the purified active peptide. Here we show that an induction of 
defensin expression in wild type animals using a topical application of sNAG 
results in an antibacterial response.  It has recently been shown that transgenic 
mouse models expressing the human defensin 5 gene are resistant to S. 
typhimurium, an infection that results in death of wild-type animals [141] again 
suggesting the importance of defensins in the regulation of the antimicrobial 
response. 
It has been accepted that the α-subtype of defensins are expressed in 
neutrophils and paneth cells, whereas the β-type defensins are epithelial in origin. 
We also see β-type defensin expression induced in response to sNAG in human 
keratinocytes both in culture and in the cutaneous wound healing model.  Our in 
vivo data illustrates that β-defensin 3 is mainly expressed in the suprabasal 
layers after treatment with sNAG.  This is consistent with previous data which 
localized human β-defensin 2 to the spinous and granular layers of the skin [142].  
The skin is in constant contact with injury and infection and functions not only as 
a mechanical barrier but also maintains the ability to mount an active defense 
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against infection.  The expression of β-defensin in the outer layers of skin 
supports their role in cutaneous innate immunity.  However, we also show that 
sNAG specifically stimulates the expression of three different α-defensins (1, 4 
and 5) in endothelial cells. We show this by RT-PCR, gene array analysis, 
immunofluorescence and ELISA (data not shown). The interaction between 
endothelial cells and leukocytes in tissue repair is one of the initial and most 
important steps in wound healing. The process of extravasation of leukocytes 
from the vasculature is initiated by chemotactic factors, therefore; it is interesting 
that α-defensins are induced by sNAG and may contribute to the necessary 
neutrophil/endothelial cellular interactions. More recently it has come to light that 
defensins exhibit biological activities beyond the inhibition of microbial cells, 
including their contribution to the adaptive immune response by exhibiting 
chemotactic activity on dendritic [76] and T cells, monocytes, and macrophages 
[77] and keratinocytes [143]. Previous work shows that human beta defensins 1 
and 2 have the ability to chemoattract immature dendritic cells and T cells 
through the CC-chemokine receptor 6 (CCR6) [79], and that human beta 
defensin 2 can chemoattract TNFα treated neutrophils via the CCR6 receptor 
[78].  Human β-defensin 2 and 3 have also been shown to induce chemotaxis by 
interacting with CCR2, a receptor expressed on macrophages, monocytes, and 
neutrophils [144].  Interestingly, we show that sNAG treatment induces both α 
and β-defensin expression in endothelial cells.  Taken together, the recent data 
suggest that defensins may mediate wound healing not only by their antimicrobial 
properties, but also by being chemotactic for other cell types necessary for 
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proper healing. However, application of β-defensin 3 alone did not result in an 
increase in wound closure (data not shown)  implying that topical application of a 
single defensin does not sustain the cellular interactions required for increased 
chemo attraction, cellular recruitment and wound closure.  
It is interesting to note that gram stains from Akt1 null infected mice show 
accumulated immune cells, likely neutrophils, which are staining positive for 
bacteria.  This may suggest that in addition to their delay in wound healing Akt1 
null mice may have immune trafficking and clearance issues. In a different Akt1 
null animal using an incisional wound assay, others have shown that the primary 
phenotype was a lack of vascular maturation (reduced smooth muscle actin 
expression), but no changes in wound closure [145]. However, there are some 
differences between these studies and ours. First, we use a full thickness “punch” 
wound. Secondly, the Akt1 null animal used here was constructed using an 
insertional mutagenesis at the translational start site. In addition, our model is on 
a pure C57/Bl6 background rather than on a C57Bl6/129 background.  It is well 
established that a genetically mixed background (especially a 129/C57Bl6 mixed 
background) increases hybrid vigor which can compensate for the loss of a 
single gene, such as Akt1, thus suppressing phenotypes in knockout animals 
[146, 147].  A full analysis of Akt1 dependent function during cutaneous wound 
healing is presently underway in the laboratory. 
Our in vivo data using both wild type and Akt1 knockout animals confirms the 
requirement for Akt1 in sNAG-induced β-defensin 3 expression.  Since mouse 
leukocytes do not express α-defensins like most other mammalian leukocytes 
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[148] in vivo α-defensin staining of infiltrating immune cells was not possible.  
Treatment of airway epithelial cells in vitro with alpha defensins 1-3 causes a 
dose and time-dependent increased cell migration that requires activation of 
PI3K and MAPK pathways [94].  We have previously shown that sNAG 
stimulation of endothelial cells results in the activation of MAPK [137] and in data 
presented here, pharmacological inhibition of MEK also inhibits the expression of 
the defensins in vitro. These findings suggest that both pathways impinge on the 
regulation of defensin expression by sNAG, however, Akt1 ablation results in a 
marked reduction of its expression both in vitro and in vivo. In myeloid cells, β-
defensin 1 expression is controlled at the level of transcription, in part, by the Ets-
family member PU.1 [149, 150]. PU.1 is a downstream target of Akt1 in the B-cell 
lineage [151].  We have shown, in primary endothelial cells that Akt1 is upstream 
of Ets1 both in vitro and in vivo during Drosophila tracheal development [122].  
sNAG stimulation of endothelial cells results in increased expression of Ets1 
(probably through Akt1) which is required for the migration of endothelial cells 
[137].  A delineation of the transcriptional regulatory mechanisms responsible for 
the regulation of the defensins by sNAG are currently underway in the laboratory.  
Thus far, sNAG treatment has resulted in a series of downstream activities; 
hemostasis, cell migration, cell proliferation, increased wound closure, and as 
described here, stimulation of the innate immune response resulting in anti-
bacterial functions. Using a custom gene chip we have also shown that a number 
of Toll-like receptors are up-regulated by sNAG treatment of human endothelial 
cells (data not shown). Toll-like receptors (TLRs) are highly conserved receptors 
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that recognize specific molecular patterns of bacterial components leading to 
activation of innate immunity.  Interestingly, Drosophila lack an adaptive immune 
system but are still resistant to microbial infections [152].  This host defense is 
the result of an innate immune system that provides protection by synthesizing 
the antimicrobial peptides dToll and 18-wheeler which are induced by TLRs [153, 
154].  Recent work has also linked human defensin expression to TLR activation.  
Human β-defensin 2 was shown to be induced in airway epithelial cells in a TLR-
2 dependent manner [155].  Toll-like receptor 4 has been shown to mediate 
human β-defensin 2 inductions in response to Chlamydia pneumonia in 
monocytes [156].  Importantly, the PI3K/Akt pathway is a key component in TLR 
signal transduction, controlling cellular responses to pathogens [157]. Since it is 
known that stimulation of TLRs can lead to increased defensin synthesis, this 
work suggests the potential for sNAG as a stimulator of innate immunity and 
bacterial clearance via the activation of Akt1.   
Given the dramatic increase of diabetic patients within the population who 
present with chronic wounds and complications due to wound infection, new 
clinical treatments are in high demand. Here, we describe marine derived 
pGlcNAc nanofibers that not only increase the kinetics of wound healing but act 
to stimulate innate immunity thus providing anti-bacterial activity. The obvious 
importance of these observations is the application to nosocomial infections. Of 
the nosocomial infections, surgical wound infections predominate; with statistics 
showing up to 8% of all surgical patients. The direct cost of these types of 
infections is approximately 4.5 billion dollars per year. Given that defensins are 
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part of the innate immune system, activation of these pathways will preclude the 
generation of resistant organisms as well as allow for the antibiotic-independent 
clearance of bacterial infection. Use of sNAG in a hospital setting would defray 
much of the cost and markedly reduce the production of antibiotic resistant 
species. Taken together, these findings suggest that these marine derived 




The inevitable result of adult wound healing is scar formation, which follows both 
surgical and trauma wounds.  Scar formation following cutaneous wounding is 
due to an unorganized deposition of excess collagen and fibrous tissue that 
replaces normal dermal tissue.  Scarring is a major medical complication that 
often results in restricted tissue movement, loss of function, poor aesthetics, and 
potential psychological distress [158].  The ability of mammals to heal without a 
scarring response (tissue regeneration), is restricted to a certain stage of 
development, after which wound healing proceeds with scarring. One major 
difference between tissue regeneration and scar formation is the organization 
and deposition of collagen. Comparisons of fetal regenerated tissue and adult 
scars show that each contains strikingly similar components, suggesting 
differences in regulation of tissue architecture and not in an abnormal molecular 
composition of the scar. Therefore tissue regeneration and scar-forming tissue 
repair share common mechanisms that may be controlled differently [159].  Fetal 
wound healing exhibit differences in the inflammatory response, TGFβ signaling, 
and hyaluronan synthesis. Fetal wounds are rich in hyaluronic acid which serves 
to facilitate an environment for cell migration and tissue regeneration.  In adult 
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wounds hyaluronic acid rapidly decreases while in fetal wounds it persists after 
persists for several weeks [160]. In addition, scarless wounds are characterized 
by a reduction in overall inflammatory responses that may be partly attributed to 
decreased platelet degranulation [161].  Decreased platelet activity results in 
reduced levels of TGFβ-1 and TGFβ-2 [161], which have established roles in the 
regulation of scarring. Reductions in these cytokines in fetal wounds correlate to 
reductions in scarring and  addition of the cytokine to scarless wounds results in 
scar formation [162]. Interestingly, addition of TGFβ-3 to adult wounds leads to a 
decrease in scar formation suggesting the ratio of the differing isoforms is critical 
to tissue regeneration and scar formation [163].  Given the impact of scar 
formation and the limited effectiveness of current treatments such as silicone 
dressings and hydrocortisone injections, the development and characterization of 
new treatments are needed [164].   
Treatment of cutaneous wounds with pGlcNAc nanofibers (sNAG) an FDA 
approved material (TalyMed™) promotes accelerated wound healing in both wild 
type animals and in those with delayed wound healing phenotypes in murine, pig, 
and human models [165-169]. Increased wound repair mediated by nanofiber 
treatment is characterized by increased hemostasis [170, 171]. Using the db/db 
mouse system, thin pGlcNAc nanofiber containing membranes placed directly 
into the wound bed profoundly accelerated wound closure mainly by re-
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epithelialization and increased keratinocyte migration, granulation tissue 
formation, cell proliferation, and vascularization compared with control wound 
treatments. These findings indicate that pGlcNAc nanofibers may provide a 
combinatorial therapy using a single FDA approved agent. 
Here we show that pGlcNAc nanofiber treatment results in reduced scarring 
where reduced scar size correlates with an increased tensile strength and 
elasticity of the healed wound. pGlcNAc treated wounds have a decreased 
collagen content, decreased myofibroblasts and increased collagen organization. 
We show that the serine threonine kinase Akt1 is required in vivo for the 
pGlcNAc-induced increases in tensile strength and elasticity. Using a fibrin gel 
assay to assess fibroblast alignment within a lattice that provides tension points, 
we show that nanofiber stimulation results in increased fibroblast alignment by a 
process also requiring Akt1. Our findings suggest that pGlcNAc nanofibers 
stimulate an Akt1 dependent pathway that results in the proper alignment of 
fibroblasts, decreased scarring, and increased tensile strength during cutaneous 
wound healing.  
 Increasing numbers of patients develop scars due to a rise in both elective 
operations and operations following traumatic injury [172].  While there are many 
current therapies on the market to reduce scar formation including flavonoid 
creams, silicone gel sheets, pressure therapy, corticosteroid injections, and 
cryotherapy, many of these therapies have resulted in controversial data and 
limited scientific studies [172].  Here, we evaluate a novel pGlcNAc nanofiber 
treatment that has been shown to increase wound healing while reducing 
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bacterial infection. Our studies suggest that pGlcNAC treatment of cutaneous 
wounds results in decreased scar formation and improved tissue quality as 
measured by increased tensile strengths.   
sNAG treatment results in decreased scar size and increased collagen 
alignment 
Our previous findings show that pGlcNAc nanofiber treatment of cutaneous 
wounds results in increased wound closure in a diabetic mouse model [128] and 
in wild type mice [165] that is due, at least in part, to increased angiogenesis, 
keratinocyte proliferation and migration, and expression of several cytokines, 
growth factors [137] and innate immune activation [165]. We have noticed that at 
long time points post wounding it is very difficult to define the scar area. We 
therefore sought to analyze the effect of sNAG on scar formation.  Excisional 
wounds were created in wild type animals which were either treated with a 
membrane form of sNAG or left untreated. At 21 days post-wounding, animals 
were sacrificed and scar sizes were measured. As shown by the quantitation in 
Figure 4.1A, sNAG treated wounds show an approximately 2-fold reduction in 
scar size as compared to untreated wounds.  To examine the amount and quality 
of collagen in treated and untreated wounds, Masson’s trichrome staining was 
performed on tissue sections from 10 days post wounding. As seen in Figure 
4.1B, sNAG treatment of cutaneous wounds results in decreased collagen 
content as indicated by less blue staining and more organized collagen alignment, 
especially as visualized at the wound borders, where new collagen in 
appropriately aligned with existing collagen. Hydroxyproline assays were 
performed to quantitatively analyze the amount of collagen deposition in treated 
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and untreated wounds. As shown in Figure 1C, sNAG treated wounds have an 
approximately 3-fold decrease in overall collagen content.   
  







	   85	  
Figure 4.1.  sNAG treatment results in decreased scar size and more 
organized collagen alignment.  (A) Quantification of scar size from excisional 
wounds of Wild Type male mice (n=3) that were either treated with sNAG 
membrane or left untreated. Scars were measured after 21 days of healing. (B) 
Masson Trichrome staining of paraffin embedded sections of cutaneous wounds 
harvested on day 10 post wounding from both WT untreated and sNAG treated 
mice. The 4x magnification illustrates the entire skin section while the 20x 
magnification is focused on the regenerating tissue directly under the wounded 
area. Boxes are included to show the regions of magnification. (C) Quantitative 
analysis of collagen content in sNAG treated wounds compared to untreated 
wounds of WT mice using a hydroxyproline assay (p<0.05).  
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Myofibroblasts are an important cell type in tissue repair and have been 
implicated in the generation of scarring via collagen production [173, 174]. 
Myofibroblast populations are reduced during fetal wound healing where scarring 
is absent [175].  To visualize the distribution of myofibroblast populations, wound 
sections were labeled with an antibody directed against alpha smooth muscle 
actin (αSMA).  As shown in Figure 4.2A and quantitated in Figure 4.2B, treated 
wounds show at least a 2-fold reduction in the expression of αSMA, suggesting 
that the reduction in collagen content are due to reduced numbers of 
myofibroblast cell number.   
sNAG treatment causes increases in tensile strength and elasticity of 
wounded skin 
Given that collagen imparts strength and mechanical properties [176] and that 
collagen deposition and scar formation differs between treated and untreated 
cutaneous wounds, we sought to measure whether sNAG treatment resulted in 
increased tensile strength and elasticity.  To measure tensile strength and 
elasticity, cutaneous wounds generated in wild type animals, both untreated and 
treated, were harvested after 21 days and subjected to mechanical testing using 
a strain gauge extensometer.  Normal unwounded skin from wild type mice was 
used as a control. Analysis of mechanical testing shows that sNAG treated 
cutaneous wounds of WT animals display an approximate 40% increase in 
tensile strength compared to untreated wounds (Fig 3A).  Additionally, sNAG 
treated wounds exhibited tensile strength recovery at levels similar to unwounded 
control skin (Fig 3A).  During tensile strength measurements, it was noted that 
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Figure 4.2.  sNAG treatment results in decreased alpha smooth muscle 
expression.  (A) Paraffin embedded sections of cutaneous wounds harvested on 
day 10 post wounding from both sNAG treated and untreated WT mice. 
Immunofluorescence (20X) was performed using antibodies directed against α-
SMA (red), and TOPRO (Blue). White arrows indicate vasculature that is also 
positively stained with α-SMA antibodies. (B) Quantitation of α-SMA expression 
from paraffin embedded sections was performed using NIH ImageJ software. 
(*p<.05) 
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sNAG treated cutaneous wounds from WT animals were more elastic than 
control or untreated counterparts.  Figure 4.3B illustrates that sNAG treatment 
results in significantly increased elasticity of the healed tissue as compared to 
both untreated cutaneous wounds and unwounded control skin.  To assess if 
sNAG treatment of cutaneous wounds results in increased elastin production, 
Van Gieson staining was analyzed.  In Figure 3C, wounds derived from treated 
animals show elastin production (as visualized by the thin black structures) in the 
newly healed wound whereas untreated wounds do not.  These findings suggest 
that sNAG treatment results in increased tensile strength as well as increased 
elasticity and supports the hypothesis that nanofiber treatment of cutaneous 
wounds decreases scarring while concurrently increasing mechanical properties 
of healing skin.   
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Figure 4.3. sNAG treatment causes increased tensile strength and elasticity 
of wounded skin. (A) Quantitation of the relative stress wounded skin could 
withstand from sNAG treated and untreated WT mice. Tissue was harvested 21 
days post wounded and subjected to mechanical testing.  Measurements are 
relative to control (CTRL) skin which was derived from unwounded tissue of WT 
animals. (B) Quantitation of skin elasticity from sNAG treated and untreated 
wounds harvested 21 days post wounding from WT animals.  Control skin was 
derived from unwounded tissue of WT animals. (C) Van Gieson staining of 
paraffin embedded tissue sections derived from unwounded skin (control), sNAG 
treated, and untreated wounds of WT animals 10 days post wounding. Blue 
arrows indicate darkly stained elastin fibers. (*p<.05, **p<.01) 
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sNAG treatment results in increased fibroblast alignment and contraction 
of fibrin gels 
Since alignment and organization of collagen fibers is likely related to appropriate 
alignment of fibroblasts [177], we utilized a fibrin gel assay to assess if sNAG 
treatment results in alignment of fibroblasts in vitro [178].  To test this hypothesis, 
fibroblasts were treated with sNAG or left untreated prior to being embedded in 
fibrin gels.  Fibrin gels were allowed to contract overnight and were then 
analyzed for contraction and sectioned for analysis of cell alignment.  A 
representative photograph of sNAG treated and untreated fibrin gels is shown in 
Figure 4A. To visualize cell alignment, the gels were sectioned and stained with 
either phalloidin or H&E.  Representative images of H&E stained gel sections 
show that sNAG treatment results in aligned fibroblasts (Fig. 4.4B).  Black circles 
indicate where pins were placed to allow tension points along which the gels 
could contract.  sNAG-treated fibroblasts radiate from the pins in a linear, 
organized manner as compared to the scattered and unorganized arrangement 
of untreated cells.  sNAG dependent fibroblast alignment was confirmed in 
human dermal fibroblasts (data not shown). In addition, sNAG-treated fibroblasts 
correlated with increased gel contraction as compared to untreated controls (see 
below). Taken together, these data suggest that sNAG treatment of fibroblasts 
results in organized cell alignment.  This alignment of fibroblasts likely results in 
the more aligned collagen fibers and increased tensile strength shown in sNAG 
treated cutaneous wounds, as seen in Figures 1-3.    
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Figure 4.4  sNAG treatment results in increased fibroblast alignment. (A) 
Representative images of gel contractions. (B) Representative images of 
Hematoxylin and Eosin stained sections of paraffin embedded fibrin gels. 
Fibroblasts were serum starved and either left untreated or stimulated with sNAG 
(50µg/mL) overnight prior to embedding in fibrin gels.  Black circles indicate 
where minutien pins are located in the fibrin gels to serve as tension points along 
which the gel contracts.   
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sNAG dependent fibroblasts alignment requires Akt1 
Findings from our laboratory show that sNAG treatment results in increased cell 
motility and angiogenesis as a result of Akt1 activation [137].  Additionally, we 
have also shown that sNAG-dependent induction of innate immunity requires 
Akt1 [165] and that Akt1 null animals do not respond to sNAG treatment. To 
determine if Akt1 is also required for the sNAG-dependent increase in fibroblast 
alignment, fibroblasts were transduced with a shRNA expressing lentivirus 
directed against Akt1 prior to embedding in the fibrin gels.  As shown in Figure 
4.5A, sNAG-treated fibroblasts contracted the gels approximately 40% compared 
to gels containing untreated fibroblasts. Gels containing sNAG-treated shAkt1 
expressing fibroblasts contracted significantly less than sNAG-treated controls. 
Analysis of H&E stained sections from the fibrin gels show that alignment is 
inhibited when Akt1 expression is blocked (Fig 5B).  As shown in Figure 5C, 
sNAG-treated fibroblasts have an increased phosphorylation of Akt as compared 
to untreated controls, suggesting activation of the Akt pathway. Since the 
knockdown of Akt1 resulted in decreased fibroblasts alignment in vitro, we 
sought to determine if tensile strength of cutaneous wounds derived from Akt1 
null animals would be affected by treatment with sNAG.  Cutaneous wounds that 
had been treated with sNAG or left untreated were subjected to tensile strength 
testing using a strain gauge extensometer as described above.  As shown in 
Figure 4.5D, there was no significant difference between sNAG treated and 
untreated wounds.  Taken together, our findings suggest that Akt1 is required for 
the sNAG-dependent alignment of fibroblasts as well as sNAG-dependent 
increase in tensile strength in vivo.   
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Figure 4.5 (A-B)  The sNAG dependent alignment of fibroblasts requires 
Akt1.  (A) Quantification of contraction of fibrin gels that were embedded with 
serum starved fibroblasts that were transduced with a SCR control lentivirus, 
sNAG treated fibroblasts, or fibroblasts that were transduced with a lentivirus 
directed against Akt1 prior to sNAG stimulation (50µg/mL). (B) Representative 
images from Hematoxylin and Eosin stained sections of paraffin embedded fibrin 
gels. Fibroblasts were serum starved and transduced with either Scrambled 
control or Akt1 lentivirus prior to sNAG stimulation (50µg/mL).    
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Figure 4.5 (C-D)  The sNAG dependent alignment of fibroblasts requires 
Akt1. (C)  Immunofluorescence of both serum starved (untreated) or sNAG 
treated fibrin embedded fibroblasts using an antibody directed against phospho-
Akt (red) and DAPI.  (D) Quantitation of the relative stress from sNAG treated 
and untreated Akt1 null animals. Tissue was harvested 21 days post wounded 
and subjected to mechanical testing.  Measurements are relative to control 
(CTRL) skin which was derived from unwounded tissue of Akt1-/- animals. 
(*p<.05) 
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Discussion 
Our findings show that highly purified pGlcNAc nanofiber (sNAG) treatment of 
cutaneous wounds results in reductions in scar formation, increased collagen 
organization in the absence of increased collagen, increased tensile strength and 
elasticity. These activities are blocked by Akt1 ablation both in vitro and in vivo. 
As  tensile strength is determined by collagen remodeling during the maturation 
phase of wound healing we suggest that pGlcNAC nanofibers stimulate an Akt1 
dependent pathway that leads to remodeling of collagen. Collagen remodeling is 
a complex process that involves both collagen synthesis and degradation by 
MMPs and other collagen binding proteins such as SPARC, followed by collagen 
crosslinking between the lysine and hydroxylysine of the peptides which is 
controlled by lysyl oxidase and lysyl hydroxylase which create stable bonds [179]. 
Akt1 is known to play a role in collagen synthesis through the control of the Ets 
family of transcription factors [180]. Ets family members are known regulators of 
MMP expression; e.g. MMP1 and 9. Taken together these findings suggest a 
central role for Akt1 in the regulation of scar formation. [181].   
pGlcNAC nanofiber  treatment leads to a more  seamless collagen fiber 
organization, suggesting that sNAG treatment increases the kinetics of wound 
resolution and remodeling and decreases in α-smooth muscle actin (αSMA), 
suggesting a decreased number of myofibroblasts in the wound. These atypical, 
activated  fibroblasts are the major producers of collagen in cutaneous wound 
healing, are active during contraction, and are cleared from the wound by 
apoptosis [174]. Our findings suggest that sNAG treatment effects the 
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differentiation of myofibroblasts, their epithelial trans-differentiation, or their 
recruitment from the stroma or from the circulation. Since our model is a total 
Akt1 null animal, it is of interest to determine which cell type is responsible for the 
effects on myofibroblast recruitment or differentiation. Akt1 is known to stimulate 
cytokine secretion in both the endothelium [137] and in macrophage/monocyte 
lineages [182]. Myofibroblasts are thought to be recruited as circulating fibrocytes 
precursors. We therefore suggest that Akt1 may be controlling their recruitment.  
To understand the role of sNAG in collagen alignment, we used a fibrin gel assay 
that provides tension lines on which cells can align and provides fibroblasts with 
a lattice similar to that which occurs during normal wound healing. Making the 
assumption that in order for collagen to be properly deposited, the fibroblasts 
themselves must be aligned. Cellular alignment is crucial for the formation of 
proper tissue architecture and provides appropriate mechanical function. Use of 
a three dimensional environment that more closely mimics an in vivo situation, 
provides an in vitro system in which to study these cellular responses. We show 
that pretreatment of fibroblasts with sNAG under serum starved conditions 
results in a marked alignment of cells toward the tension poles and that aligned 
cells physically contract the fibrin clot. Both  the contraction and alignment is 
ablated under conditions of Akt1 knockdown. Interestingly, we see a slight but 
reproducible increased Akt phosphorylation in aligned cells. These findings show 
that Akt1 is required for sNAG-induced cellular alignment in vitro. Akt1 null 
animals validate these findings since the tensile strength of wounded skin is not 
affected by sNAG treatment in this model.  
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Exactly how sNAG activation of Akt1 results in fibroblast alignment remains to be 
determined. Akt signals to the cytoskeleton via the Rho-family of GTPases and 
PAC1, among others, controlling cytoskeletal remodeling [183]. Akt can directly 
phosphorylate vimentin, an intermediate filament protein involved in cell shape 
and motility changes [184]. In motile cells, phospho-Akt is localized to the leading 
edge whereas in apical/basal polarized cells, phospho-Akt tends to be localized 
to the cell periphery. These findings suggest that Akt plays a role in cell polarity, 
cytoskeletal organization and directed cell movement. The general consensus in 
fibroblasts, as determined by both knockdown and over expression analyses, is 
that Akt1 positively directs migration while Akt2 blocks migration [185]. The 
inverse is true in epithelial cells. In the fibrin gel assay presented here, Akt1 is 
required for the sNAG-induced alignment of cells between two tension points. 
Akt1 must then be required for cytoskeletal rearrangement and cellular 
positioning, possibly affecting front to back cell polarity. The exact mechanisms 
as to how Akt1 specifically affects this cell polarity in response to tension is 
currently under investigation. It is interesting to note that Akt1 null and wild type 
animals have similar tensile strengths of unwounded skin (data not shown).  This 
suggests that the cellular programs controlling skin development are intact in the 
absence of Akt1. The double Akt1/Akt2 null animal, in addition to dwarfism and 
early neonatal lethality, presents with a thin skin phenotype, characterized by a 
marked reduction in the number of cells within each skin layer. This phenotype is 
due to a lack of proliferation that cannot be compensated by Akt3 alone [138].  
Interestingly, the presence of either Akt2 or Akt3 does not affect sNAG stimulated 
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wound repair and tensile strength as discussed here, or the  clearance of 
infection and wound closure as previously reported [165].  This demonstrates 
that these two kinases are not functionally redundant for sNAG induced tissue 
repair or antimicrobial effects.   
We also show that sNAG stimulation results in an increased elasticity as 
compared to both unwounded and wounded skin. Elasticity is conferred by 
elastin fibers formed during development.  Elastin synthesis is absent in the adult 
but can be induced following injury through the up regulation of certain cytokines 
and growth factors, e.g. insulin-like growth factor-1 (IGFI) and interleukin 1 (IL-1), 
but is aberrantly deposited and is not detected until months after healing. 
Aberrant deposition of elastin leads to decreased elasticity and flexibility of the 
scar [186, 187] and is characterized by short, thin, immature fibers. sNAG 
treatment causes increased in elastin fiber staining that is visually similar to 
unwounded skin and correlates to increased trophoelastin protein expression and 
skin elasticity. Elastin expression is controlled, at least in part by IL-1 and IGF-1 
and we show, at  least in vitro, sNAG stimulation results in an increased 
expression of IL-1, suggesting a connection between this Akt1 and  elastin fiber 
staining [137].   It is well established that Akt1 is a major kinase functioning 
downstream of both IL-1 and IGF-1. 
In general, Akt1 has been linked to extracellular matrix assembly and fibronectin 
organization via the activation of β1 integrins [188]. Our previously published 
findings show that sNAG specifically activates integrin-dependent signaling and 
that this leads to Akt1 activation [189]. Therefore, it is possible that elastin 
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deposition in the sNAG stimulated wounds is due to an integrin/Akt1 dependent 
pathway. Given that elastin fiber deposition does not generally occur in the adult, 
it will be important to understand the mechanisms by which sNAG stimulates 
elastogenesis for future application to skin repair and tissue bioengineering.  
Our findings suggest a model (Fig. 4.6) by which sNAG nanofibers stimulate 
outside-in integrin signaling that results in an activation of Akt1 which controls 
cellular alignment under tension, and reductions in collagen I deposition and scar 
formation. Given that scarring is a major medical complication that causes 
decreased tissue function and aesthetics and the limitation of current treatment 
options, treatment of cutaneous wounds with this FDA approved material can be 
used to provide hemostasis, increased wound healing kinetics, increased innate 
anti-microbial responses and decreased scarring and increased function, thus 
providing combinatorial therapy using a single FDA approved agent.  
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Figure 4.6. Model of sNAG-dependent regulation of collagen alignment and 
tensile strength.  An illustration showing the interaction between pGlcNAC 
nanofibers and integrins, upstream of Akt1, that leads to increased collagen 







We have shown that pGLcNAc treatment of full thickness cutaneous 
wounds results in more rapid healing, increased expressions of antimicrobial 
peptides, and decreased scarring.  Our data suggests all of these pGlcNac 
dependant effects are regulated through Akt1.  Our in vivo studies also show that 
mice deficient in Akt1 show a delayed healing response that is not rescued or 
improved by treatment with pGlcNAc nanofibers.  Additionally, AKT1-/- mice 
treated with the nanofiber do not show increased tensile strength or appropriate 
collagen alignment as compared to Wild Type treated animals. These data 
suggest AKt1 may play a critical role in tissue regeneration and remodeling.   
Myofibroblasts are well established as critical cells in tissue remodeling, 
contraction, and scar formation.  Force generation by these cells depends on the 
contraction of stress fibers and is mediated through Rho/Rho-kinase  (ROCK) 
and its inhibition of myosin phosphatase [190].  Activated ROCK promotes the 
contraction of isolated stress fibers and could result in a long-lasting tensile 
activity [191].  Studies to determine the role of Rho- kinase in stress fiber 
organization show that treatment of cultured fibroblast with rho-kinase inhibitors 
results in stress fiber disassembly [191].  Investigation of collagen matric 
contraction after treatment with either AKt1 or Rho-kinase inhibitors further 
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elucidate the signaling involved. Interestingly, pharmacologic inhibition of both 
Akt1 and Rho-kinase resulted in complete inhibition of the matrix contraction 
[192].  These data raise the possibility that Rho signaling may play an important 
role in myofibroblasts activation and scar formation in our model.   While the 
signaling is complex and a significant amount of cross talk exists, some evidence 
indicates that Rho GTPases may suppress or inactivate AKT [193].  Therefore, a 
lack of active Akt may lead to increased Rho resulting in increased stress fiber 
formation in myofibroblasts and contraction of tissue.  This also raises the 
interesting possibility that treatment with pGlcNAC nanofibers inhibits expression 
of Rho GTPases through the activation of Akt1 resulting in decreased scar 
formation.  While speculative, it would be interesting to determine the expression 
of Rho GTPases in our wound healing model and to determine the effect, if any,  
of pGlcNAc nanofiber treatment.  
Transcriptional Regulation of Defensins 
Previously published data from our lab positioned Akt1 upstream of Ets1 
transcription factor in human primary EC [122].  ETS transcription factors have 
been linked to diverse biological roles. Several ETS domain proteins have been 
shown to play a role in angiogenesis and vasculogenesis [194] while others, 
PU.1 specifically, plays a role in the differentiation of lymphoid and myeloid 
lineages [195].   We have shown here, for the first time using in vitro 
experimentation, that primary EC express defensins (α1,α4,α5, and β3) when 
stimulated with sNAG nanofibers and that this expression is Akt1 dependent.  
Others have shown that β-defensin expression is controlled on the level of 
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transcription [150] but little is known about the regulation of α-defensins.   β-
defensins are known to be regulated by NFkB and the Ets family, both of which 
are downstream of Akt1 [196].  Since ETS1 as well as other Ets family members 
are positioned downstream of Akt1 in primary endothelial cells and since 
inhibition of Akt1 leads to decreased defensin expression, it is likely that 
nanofiber activation of defensins is dependent on the Akt1àETS pathway. Using 
Genomatix software, we have mapped Akt1 dependent transcription factor 
binding sites in the promoter regions of α- defensins 1, 4, and 5.  Interestingly, all 
three α-defensins have an evolutionarily conserved ETS binding site directly 
upstream of the mRNA transcription start site.   
Our data has shown that defensin expression is regulated at the level of 
transcription and that transcriptional activity is induced by treatment with the 
nanofiber.  Message stability was measured by assessment of heteronuclear 
RNA.  Endothelial cells that were serum starved prior to nanofiber stimulation 
were assessed for defensin expression using intron spanning primers.  To 
examine the role of the Aktà Ets family in the transcriptional regulation of 
defensin expression, we cloned a 500 base pair region upstream of the 
transcription start site of alpha defensins 1 and performed site directed 
mutagenesis to achieve a point mutation in the ETS site.  Wild Type and mutated 
plasmids were transformed and luciferase assays were performed to examine 
promoter activity. We show that nanofiber treatment results in increased 
transcriptional activity but we have not yet been able to show that the mutant 
ETS has an effect.  We will continue to determine if Ets is implicated in the 
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transcriptional regulation of defensin expression.  If Ets-binding sites are 
implicated in transcriptional regulation, each site can be assessed by CHIP 
(Chromatin immunoprecipitation) analysis to determine specifically which Ets 
family members are binding to the promoter.  
  












Figure 5.1 Schematic of Akt1 dependent transcription factor 
binding sites.  Using Genomatix software, 500 bp upstream of the 
transcription start site was analyzed for conserved Akt1-dependent 
transcription factor binding sites on the mRNA of α-def 1, 4, and 5.  
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                Figure 5.2 (A-D).  A)Endothelial cells were serum starved and pre-
treated with Actinomycin D prior to sNAG stimulation and assessed for 
expression of α-defensin 1. B) Endothelial cells were serum starved 
prior to stimulation with sNAG and assess for expression of of α-
defensin1.  C) Endothelial cells that were serum starved prior to 
nanofiber stimulation were assessed for defensin expression using 
intron spanning primers to determine heteronuclear RNA at  the noted 
time points.  D) A 500 base pair region upstream of the transcription 
start site of alpha defensins was cloned and site directed mutagenesis 
to achieve a point mutation in the ETS site was completed. Wild Type 
and mutated plasmids were transformed and luciferase assays were 
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The Role of EPSTI1 in Cutaneous Wound Healing 
 
 Here, we have shown that pGlcNAc treatment of cutaneous wounds 
results in a smaller scar that has increased tensile strength and elasticity.  
Additionally, pGlcNAc treated wounds exhibit decreased collagen content, 
increased collagen organization and decreased myofibroblast content.   Our data 
presented here provides evidence that Akt1 is central to pGlcNAc dependent 
activities. While we were able to show that Akt1 plays a role in fibroblast 
alignment with in a fibrin gel model, the exact mechanism and signaling remain 
unclear. Transcriptome analysis of nanofiber treated cells shows induction of 
many interferon-responsive genes such as Epithelial Stromal Interaction Protein 
1 (EPSTI1), a novel protein involved in epithelial/stromal interactions Table 5.1 
String analysis, a program that analyzes protein interactions, indicates that this 
novel protein may interact with alpha defensins as well.  (Figure 5.3) 
Additionally, we now have new and exciting data that EPSTI1 is up-regulated in 
nanofiber treated wounds of WT but not in similarly treated Akt1-/- animals 
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Top	  20	  genes	  Upregulated	  by	  sNAG	  treatment	  of	  EC 
Cytidine	  monophasphate	  kinase 
Chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  10 
Radical	  S-­‐adenosyl	  methionine	  domain	  containing	  2 
2'-­‐5'-­‐oligoadenylate	  	  synthesase-­‐like 
Receptor	  (chemosensory)transporter	  protein	  4 
Interferon-­‐induced	  transmembrane	  protein	  1	  (9-­‐27) 
Myxovirus	  (influenza	  virus)	  resistance	  1,	  interferon-­‐inducible	  protein	  p78 
Interferon-­‐induced	  protein	  with	  tetratricopeptide	  repeats	  1 
Epithelial	  stromal	  interaction	  1	   
Myxovirus	  (influenza	  virus)	  resistance	  2 
Interferon-­‐induced	  protein	  with	  tetratricopeptide	  repeats	  3 
NPC-­‐A-­‐7 
ISG15	  ubiquitin-­‐like	  modifier 
Interferon,	  alpha-­‐inducible	  protein	  6 
Bone	  marrow	  stromal	  cell	  antigen	  2 
Proteosome	  subunit,	  beta	  type,	  9 
Interferon-­‐induced	  protein	  with	  tetratricopeptide	  repeats	  2 
solute	  carrier	  15 




Table 5.1  illustrating the top genes up regulated by sNAG in endothelial 
cells treated with 10µg/ml nanofiber under serum starved conditions for 24 
hours and subjected to whole transcriptome analysis 




Figure 5.3  Illustration derived from String analysis, a program that analyzes 
protein interactions.  
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Figure 5.4	   	   (A) Serum starved EC were stimulated with nanofibers for times 
indicated and assessed for EPSTI1 expression.  (B) Analyses of sNAG stimulated 
EC infected with a scrambled control or Akt1 shRNA lentiviruses and assessed for 
expression of EPSTI1 
A.	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Figure 5.5  Representative images of wound sections derived from treated and 
untreated WT and AKT1-/-animals labeled with antibodies directed against 
EPSTI1. (B) Quantification of EPSTI1 staining in wound tissue sections using 
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We have defined the cell type in the wound bed that express EPSTI1 as 
fibroblasts using a series of cell markers including hsp47 (a collagen chaperone) 
and vimentin.  While little is known about this protein or its subcellular 
localization, we have shown that EPSTI1 does not co-localize with KDEL (marker 
for endoplasmic reticulum).  While we have show that EPSTI1 functions down 
stream of Akt1 in vitro, we have been unable to define a specific and definite role 
for EPSTI1 in fibroblast alignment and wound healing. Previously we showed that 
ablation of Akt1 expression in embedded fibroblasts lead to decreased cellular 
organization. Unfortunately, knockdown of EPSTI1 in fibroblasts provided 
inconclusive results in our fibrin gel assays.  Indeed, more studies are needed to 
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Figure 5.6 ( A) Tissue was harvested from WT mice 10 days post wounding and 
analyzed for expression of Hsp47, EPSTI1, VImentin, and DAPI.  (B)  Tissue was 
harvested from WT Mice 10 days post wounding and analyzed for expression of 
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Oral Wound Healing vs. Cutaneous Wound Healing 
Due to an interest and profession concerning dentistry and the oral cavity, 
a comparison of cutaneous healing and oral mucosal healing seems fitting? To 
elucidate the similarities and differences between healing within the different 
environments, each stage of wound healing will be compared.  While oral wound 
healing progresses through the same stages of healing [197] the oral mucosa 
heals at a much faster rate and with a lack of scarring [198].  Animal studies 
comparing both cutaneous and mucosal excisional wounds show that while 
neutrophil infiltration follows a similar time course in both models, the overall 
number of neutrophils were significantly reduced in oral wounds at all time points 
measured [198].  Previous data using a db/db cutaneous would model showed 
that a reduction in inflammation and inflammatory cytokines is associated with 
improved tissue repair [199].   Additionaly, oral mucosal wounds exhibit 
significantly decreased macrophage infiltration [198, 200] and expression of 
inflammatory cytokines IL-6 and IL-8 as compared to dermal wounds [198].  Data 
also suggests that macrophages may play in important role in scar formation 
[201].  Comparison of cutaneous and oral mucosal wounds indicate that oral 
wounds show a brief increase in macrophage expression, but at later time points 
(days 14, 28, and 60 days post wounding), skin wounds exhibit; significant 
increases in the number of macrophage as compared to oral wounds [200].  Mast 
cells, while best known for their role in allergies and allergic responses, have also 
been shown to play a prominent role in wound healing and scar formation [201].  
As with macrophages, oral musical wounds contain significantly fewer mast cells 
compared to skin wounds at 60 days of healing [200].   
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A comparison of oral mucosa wounds and cutaneous skin wounds in the 
Duroc pig also elucidated differences in the cellularity and myofibroblasts 
response.  The density of cells with normal fibroblast morphology was 
significantly lower in oral wounds as compared to skin wounds.  Interestingly, the 
fibroblasts were aligned perpendicular to wound edges in the oral mucosa while 
skin wounds showed randomly arranged, atypically round fibroblast cells [200].  
After 60 days, the orientation, density and maturity of collagen fibers were 
comparable to that of unwounded tissue in the oral mucosal wounds as 
compared to skin indicating that of mucosal wounds showed better regeneration 
of connective tissue organization [200] 
Scar formation 
As with cutaneous wound healing, the exact mechanisms governing healing and 
scar formation are unknown in the oral environment. Studies comparing the oral 
mucosa and cutaneous wounds in red Duroc pigs shows that oral wounds exhibit 
significantly less scarring both clinically and histologically [202].  As discussed 
previously, levels of TGFβ correlate to scar formation.  As would be expected, 
oral mucosal wounds show decreased levels of TGFβ  and smad3 positive cells 
[200].  Additionally, cutaneous scars contained a significant number of  type I 
procollagen immunopositive cells and an increased fibronectin content, while the 
oral mucosal wounds demonstrated accumulation of tenascin-C, an extracellular 
matrix molecule that is abundantly expressed in embryonic scarless wound 
healing [202].  Comparison of dermal fibroblasts and oral mucosal fibroblasts 
show that dermal cells embedded in collagen gels possess greater contraction 
	   121	  
potency [203]. Collagen gels embedded with fibrobalsts serve as a valuable 
model for studying wound closure.  Wounding of the gel results in fibroblasts 
migration toward the defect and closure of the gel edges [204], likely simulating 
wound contraction and scar formation.  
As with dermal wound healing, individuals with compromised health 
exhibit delays in oral mucosal wound healing.  Delayed vascularization, 
decreased innate immunity, and decreased growth factor production may be 
involved in the delayed healing seen in the oral mucosa of diabetic patients [205].  
Since diabetic patients are immunocompromised, infection is of particular 
concern while patients are healing. Compounding this issue, reports indicate 
these patients also exhibit suppression of innate immunity. Diabetes results in 
decreased neutrophil migration from the vasculature as well as decreased 
chemotactic activity of neutrophils [206].  Interestingly, several types of 
antimicrobial peptides are produced by the oral epithelium, and the expression 
levels of beta-defensins are affected by the concentration of insulin and glucose 
[207].  In addition to a decreased innate immune response, diabetic patients also 
suffer from reduced salivary flow.  Saliva is a critical component in the oral cavity 
and functions in digestion, antimicrobial activity, and cleaning or rinsing of the 
oral mucosa surfaces.  The reduced saliva and reduced antimicrobial peptide 
expression present in diabetic patients likely contributes significantly to altered 
wound healing of the oral mucosa.   
While similar mechanisims are involved when comparing oral mucosal 
healing to cutaneous wound healing, oral healing presents with a more 
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regenerative type of healing that is comparable to fetal wound healing. With this 
in mind, are there any potential therapeutic uses for pGlcNAc nanofibers in the 
oral cavity?  Very recent data indicates that oral bacteria result in keratinocyte 
apoptosis and delayed oral wound healing [208]. The antimicrobial properties of 
pGlcNAC nanofibers may be useful for oral wound healing in both the healthy 
and the diabetic patient. As previously discussed, patients afflicted with diabetes 
heal poorly and suffer from decreased innate immunity and defensin expression. 
In theory, pGlcNAc nanofibers could also prove useful in the treatment of oral 
mucositis as a result of cancer treatment.  Oral mucositis is a common and 
debilitating complication of head and neck radiation. Currently, most treatment 
modalities for oral mucositis are only supportive in nature.  The effect of 
pGlcNAC nanofibers  treatment on epithelial cells raises the question of potential 
therapeutic value for this painful and debilitating side effect of cancer treatment.  
While the pGlcNAc nanofibers we have studied have not been evaluated in the 
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